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ABSTRACT 
Radiotherapy, endocrine therapy, chemotherapy and targeted therapy adjunct to surgery have 
a critical role in the management of early breast cancer for outcome improvement. 
Anthracycline containing chemotherapy reduces 10-year incidence of breast cancer mortality 
by an absolute 6.5% compared to no adjuvant chemotherapy and addition of taxanes to 
anthracycline regimes leads to additional gain of 2.8% in 8-years breast cancer mortality. 
Dose dense chemotherapy improves breast cancer mortality by an estimated relative 
reduction of 40%. Trastuzumab, the first anti-HER2 agent among plenty, administered for 
one year, led to a paradigm shift in the management of HER2 positive breast cancer and 
significantly altered prognosis. Adjuvant trastuzumab improves disease free survival by a 
relative risk reduction of 40%. Despite beneficial effect of chemotherapy and anti-HER2 
targeted therapy, acute or late toxicity can be dose limiting and even influence patients’ 
quality of life during treatment and long time after it is completed. Given the good prognosis 
of breast cancer and the millions of breast cancer survivors, therapy related toxicity affects a 
considerable number of women. Efforts to escalate or de-escalate treatment are ongoing and 
potential trade-offs in safety are monitored, resulting at best to improved benefit-risk balance. 
The aim of the current thesis was to examine heart failure outcomes and management after 
breast cancer diagnosis compared to a population of women with heart failure and toxicity 
outcomes related to tailored dose dense chemotherapy namely, cardiotoxicity after 
combination with trastuzumab, neutropenia related events and premature ovarian 
insufficiency. 
The Swedish Registry for heart failure (SwedeHF) and the national health care registries were 
utilised for the purposes of Paper I. Patients enrolled in the SwedeHF registry between 2008 
and 2013 were included and followed for a median period of two years. Patients with breast 
cancer history, identified through the National Cancer Registry, and age-matched controls 
(1:5) were investigated. Heart failure related baseline characteristics and outcomes did not 
differ amid presence of breast cancer history among women registered in the SwedeHF 
registry with incident heart failure. Differences in the history of myocardial infarction, 
administration of aspirin and device therapy were observed among women with prevalent 
heart failure, depending on previous breast cancer history. Breast cancer history did not alter 
heart failure outcomes but time from heart failure diagnosis did; women with prevalent heart 
failure had worse survival than those with incident heart failure. 
Papers II-IV investigated different toxicity aspects related to the population enrolled and 
treated in the PANTHER phase III study comparing tailored (protocol predefined dose 
escalation or de-escalation) and dose dense (every two weeks) chemotherapy to standard dose 
three weekly chemotherapy. Paper II, investigated if tailored dose dense chemotherapy can 
further improve trastuzumab efficacy, compared to combination with standard chemotherapy 
and whether this combination would jeopardise cardiac safety; both parts of the study were 
predefined. The trastuzumab and tailored dose dense group demonstrated a 32% relative 
improvement in risk for breast cancer relapse but the results did not reach formal statistical 
significance. Despite small reductions of left ventricular ejection fraction at four- and six-
years follow-up, no clinically meaningful difference in the risk for cardiotoxicity was 
demonstrated between tailored dose dense chemotherapy and standard chemotherapy 
compared as administration per HER2 treatment or as per chemotherapy group. 
Compliance to the planned chemotherapy schedule is related to better breast cancer 
outcomes, underscoring the value of prophylactic granulocyte-colony stimulating factor (G-
CSF). Efficacy of G-CSF in preventing neutropenic events and delays in the delivery of the 
planned chemotherapy dose were examined in a secondary analysis in Paper III. 
Administration of G-CSF reduced the risk for neutropenic events defined as febrile 
neutropenia or infection with low absolute neutrophil count. Although a comparison between 
the two treatment groups was not possible, within group investigation in the standard 
chemotherapy group revealed improved adherence to planned schedule by fewer dose delays 
when G-CSF was administered.  
Chemotherapy-induced amenorrhea is a therapy-related adverse event but it also improves 
breast cancer survival. Efficacy of dose dense chemotherapy has been assumed to derive from 
increased incidence of chemotherapy-induced amenorrhea. Thus, the exploratory, post hoc 
studies in Paper IV investigated the incidence of chemotherapy-induced amenorrhea and 
impact on treatment outcomes, excluding patients receiving gonadotropin releasing hormone 
agonists. Even though the delivered mean chemotherapy doses in the experimental treatment 
group were higher than in the standard chemotherapy group, amenorrhea incidence at two 
years of follow-up between the two treatment groups did not differ. Hence, benefit of dose 
dense chemotherapy is deemed to stem from chemotherapy effect per se and not aggravated 
gonadal toxicity. Breast cancer relapse events were too few to make any inference on the 
impact of amenorrhea on breast cancer relapse outcomes and longer follow-up is required. 
Menstruation status did not impact efficacy of allocated treatment although a non-significant 
benefit from tailored dose dense chemotherapy was demonstrated and persisted in most breast 
cancer subgroups. Sub-group analysis of the different breast cancer subtypes did not reveal 
any influence of the baseline menopause status on the efficacy of given chemotherapy 
schedule, except in triple negative breast cancer. There is no known biological plausibility to 
explain this interaction and the possibility of a chance finding cannot be excluded. 
In summary, at median follow-up of two years, having previously been diagnosed with breast 
cancer did not alter heart failure outcomes, compared to controls, although some limited 
discrepancies in existing comorbidities and heart failure treatment were observed. Moreover, 
increasing dose intensity did not relate to excess cardiotoxicity when combined with 
trastuzumab, did not increase the risk for neutropenic events, provided G-CSF prophylaxis is 
administered, and did not affect risk for premature ovarian insufficiency. Conclusively, 
patients with early breast cancer should be offered efficient breast cancer therapy related to 
their risk level, with proper supportive therapy and assessment of potential comorbidities 
such as cardiovascular risk factors. 
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BACKGROUND 
1.1 Epidemiology of breast cancer 
Breast cancer is the fifth leading cause of death among women in high-income countries and 
the leading cancer site among women in Europe in 2018, according to the World Health 
Organization (WHO) reports (1, 2). Worldwide breast cancer incidence and 5-year 
prevalence in 2018 was estimated at about 2.1 and 6.9 million respectively; about one in four 
women diagnosed with cancer (1). Figures 1 and 2 present global cancer epidemiological data 
among women reported in 2018; incidence (according to diagnoses, not individuals) and 5-
year prevalence, respectively (3). Notably, male breast cancer is rare and comprises only 
approximately 1% of all breast cancer diagnoses (4).  
 
 
 
 
 
Figure 1. Global estimated cancer incidence (total number of diagnoses) among women of all ages in 2018. 
(Globocan 2018, IARC. Non-melanoma skin cancer excluded). 
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Figure 2. Global estimated 5-year cancer prevalence among women of all ages in 2018.  
(Globocan 2018, IARC. Non-melanoma skin cancer excluded). 
 
Incidence of breast cancer has increased over time due to the introduction of mammography 
screening and ageing of the world’s population (5, 6). Forouzanfar et al reported a three-fold 
increase of breast cancer incidence between 1980 and 2010, with a 3.1% annual rate of 
increase (7). At the same time, survival rates have been greatly improving, largely because of 
early detection due to screening, advances in the systemic therapy of breast cancer and 
improved comprehension of the disease biology and the importance of lifestyle factors (8). 
Breast cancer survival is continuously improving over time but in Europe there are still 
persisting differences between countries, with reported worse survival in eastern and parts of 
southern Europe (9, 10). Global differences between breast cancer incidence and mortality in 
Sweden and Europe are depicted in figure 3. In Sweden, 7 558 women were diagnosed with 
breast cancer in 2016 and age-standardized incidence in 2018 was estimated to 89.8 
individuals per 100 000 inhabitants (11, 12). Mean age of diagnosis is 66 years and 86.1% of 
the affected women are alive and breast cancer free 10 years after diagnosis (12). In line with 
other western countries, breast cancer mortality rate in Sweden remains low despite increased 
incidence over time, as demonstrated in figure 4 (12).  
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Figure 4. Breast cancer incidence and mortality trend over time in Sweden. (Cancer i siffror 2018, 
Socialstyrelsen och Cancerfonden i samarbete). 
1.2  Risk factors and aetiology 
Further understanding of breast cancer aetiology is of outmost importance for the 
development of intervention and prevention strategies. Exposure to endogenous and 
exogenous oestrogens, increased age, ionising radiation, high mammographic breast density, 
previous history of breast lesions and genetic predisposition increase the risk for developing 
breast cancer (13). Exposure to oestrogens refers to both intrinsic factors, such as early 
menarche and late menopause, and extrinsic factors such as low- or nulliparity, delayed first 
pregnancy, and menopausal replacement therapy (13-15). Despite some difference in the risk 
levels, all types of systemic menopausal replacement therapy have been associated to excess 
breast cancer incidence and increased breast cancer mortality, with a risk upsurge with longer 
duration of treatment (15, 16). Additionally, modifiable lifestyle factors such as 
postmenopausal obesity, lack of physical exercise, alcohol and tobacco use have also been 
identified to increase breast cancer risk (17). 
About 5-10% of all female breast cancer is attributed to genetic predisposition (18).  Women 
with triple negative breast cancer have a higher probability of having a hereditary breast 
cancer and are reported to be almost 6 times more likely to have a BRCA1 mutation 
compared to women with other subtypes of breast cancer (18, 19). Germline mutations in 
BRCA1 and BRCA2 account for about 30% of hereditary breast cancer but other less 
frequent gene mutations have also been described, such as TP53, PTEN, CHEK2, PALB2 
and ATM (18, 20-23). Even in men, BRCA1 or BRCA2 germline mutations increase the 
lifetime risk for breast cancer up to 10% (24). The affected individuals usually present with a 
strong family history and are younger at diagnosis, mandating penetration of family history 
among both men and women diagnosed with breast cancer (18). 
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1.3  Breast cancer screening and diagnosis 
Even though early detection is often cited to improve breast cancer outcomes, the impact of 
mammography screening on breast cancer mortality is debated (25). Comparisons of breast 
cancer mortality before and after mammography screening adaptation show little benefit on 
mortality solely on screening whereas a UK-based independent panel estimated that available 
published data imply a 20% survival improvement among women that are offered 
mammography screening between the age of 50 and 70 years. Controversial survival benefit 
is often juxtaposed to potential harms such as overdiagnosis and overtreatment, but the 
possibility of early diagnosis of asymptomatic women with low tumour burden that can 
potentially lead to de-escalation of cancer therapy should not be neglected (26, 27).  
Many countries have adapted mammography screening, but participation, age intervals and 
frequency of mammograms vary widely. In Sweden, the National Board of Health and 
Welfare recommends population-based screening of women between 40 and 74 years old 
every 18-24 months, but regional variations exist. Internationally, there is currently a large 
interest towards development of risk-adapted screening aiming to allow for personalised 
screening and intervention methods (28). However, no meaningful benefit on survival has yet 
been reported and formal recommendations are lacking, except for women with increased 
breast cancer lifetime risk (above 20%), where magnetic resonance imaging (MRI) screening 
is recommended (29, 30).  
Lege artis investigational inquiries of breast symptoms or a lump in the breast include 
combination of three modalities, so called triple diagnostics; physical examination of the 
breast and regional lymph nodes, imaging with mammography and ultrasound and fine 
needle aspiration or core biopsy (6). MRI of the breast can also be utilised in selected cases, 
for example pre-treatment staging in women with tumour difficult to define or in selected 
cases of lobular breast carcinoma (31). 
1.4  Clinical and genomic assessment 
Complete classification, staging and characterisation of the tumour is mandatory and 
constitutes the basis for treatment recommendations. The assessment includes both 
prognostic (distinguish patients more likely to have better or worse outcome, regardless of 
treatment) and predictive (predict benefit, or lack thereof, from specific intervention) 
biomarkers. Some of the available biomarkers are dual; for example amplification of the 
human epidermal factor receptor 2 (HER2) predisposes to worse breast cancer outcomes but 
simultaneously predicts benefit from treatment with anti-HER2 agents.   
A robust pathology report should include (32):  
a) Histological type according to the WHO classification system. The most common 
among the 19 different major subtypes of breast carcinomas, are invasive carcinoma 
of no special type (up to 75%) and lobular carcinomas (5-15%) (figure 5) (32). 
b) Histological grade according to the Elston-Ellis grading system based on mitotic 
count, nuclear polymorphism and proportion of tubule formation (33). As described 
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in table 1, each parameter is scored from one to three and grading is thereafter 
classified according to the sum of the three variables to: grade I well-differentiated 
(sum equals 3-5 points), grade II moderately-differentiated (6-7 points) and grade III 
poorly differentiated (8-9) points (33, 34). Mitotic count is counted in hot spots and 
per 10 fields but discrepancies between different microscopes should be taken into 
consideration.    
c) Existence of tumour emboli in small vessels surrounding the tumour; described as 
lymphovascular invasion (32). 
d) Stage of the tumour according to the Union for International Cancer Control (UICC) 
TNM system describing tumour size (T), nodal status (N) and the existence or absence 
of metastatic lesions (M) (32). Staging is preoperatively estimated clinically and 
radiologically by assessment of the tumour size, the existence (or not) of palpatory or 
pathologically enlarged axillary or supraclavicular lymph nodes and known macro-
metastatic lesions. The pathological TNM stage is subsequently described according 
to measurements of the resected tumour specimen and lymph nodes. 
e) Surgical margins, described as mm. In invasive breast cancer, positive margin is 
defined by “ink on tumour” (35). 
f) Axillary node status (32). 
g) Testing for expression of oestrogen (ER) and progesterone (PR) receptor and HER2 
amplification is imperative. The testing is performed primarily on protein lever 
through immunohistochemistry (IHC). However, for HER2 the IHC assessment is 
accompanied by in-situ hybridisation if immunohistochemistry shows ambiguous 
results (reported as 2+).  
h) The Ki67 score; a tumour proliferation and growth biomarker. The score should be 
reported according to international and institutional guidelines. There is a substantial 
inter-observer variability and Ki67 can also be affected by other factors such as long 
time before tissue sections, long time in room temperature and use of fixation 
solutions other than neutral formalin (36). Due to disparities between laboratories, 
local cut-off values apply. In samples with hot spots, these should be evaluated and 
reported. Digital pathology is expected to further improve reliability and 
reproducibility of Ki67 scoring (36, 37). 
 
 
 
 
  7 
 
 
 
Figure 5. Ductal breast carcinoma of no special type. Courtesy of Dr Felix Haglund 
 
 
Parameter Score 
Tubule formation Nuclear pleomorphism Mitotic counts  
Majority of tumour Regular uniform cells <8 1 
Moderate Moderate increase in size and 
variability 
8-16 2 
Little or none Marked variation >16 3 
Table 1. Histological grade according to the Elston Ellis system. 
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1.5  Intrinsic molecular breast cancer subtypes 
Perou et al described distinct molecular patterns in breast cancer samples and paved the way 
for a more tailored, tumour biology-guided classification and management of both early and 
metastatic breast cancer (38). The different gene expression patterns led to 4 clusters: basal-
like, HER2+, normal-breast-like and luminal/epithelial (38). Given the global heterogeneity 
of access to gene expression analysis, IHC is currently used as a surrogate test to distinguish 
the different molecular subtypes and it identifies five distinct intrinsic subtypes (39-41): 
Luminal A: Represent the most common molecular subtype of breast cancer (60-70%) and is 
characterised by low proliferation measured by Ki67, strong ER and PR expression and are 
usually HER2 negative. 
Luminal B-like HER2-: Account for about 10-20% of breast cancers and is characterised by 
ER expression, PR expression lower than luminal A, high proliferation according to Ki67 and 
lack of HER2 expression. 
Luminal B-like HER2+: Characterised by the same biomarkers as above but with additional 
expression of HER2. 
HER2-enriched (non luminal): Present with high proliferation, HER2-expression but lack ER 
and PR expression. All HER2-positive cancers, regardless ER/PR status, account for about 
15% breast cancers. 
Triple-negative (TNBC): Lack both endocrine receptors (ER and PR) and HER2 expression 
and is commonly accompanied by high proliferation. 
Notably, the histopathologically identified subtypes do not entirely overlap with the 
molecular subtypes (42). For example, only 71% of TNBC are classified as basal-like and not 
all HER2 positive tumours identified by IHC are HER2 enriched (43). Furthermore, 
subsequent studies have revealed intratumoural heterogeneity with significant impact on 
survival (44). More importantly, discrepancies of ER, PR and HER2 expression between the 
primary tumour and relapse shed light on tumour-evolutionary aspects with major bearing on 
breast cancer care (45). A retrospective analysis including patients with breast cancer relapse, 
revealed up to one third (32.4%) of the patients had altered ER expression at relapse, directly 
affecting chances of survival (46). Additionally, PR and HER2 expression was altered in 
40.7% and 14.5% respectively (46). A similar study reported significant deterioration of 
overall survival among 14.2%, respective, 39.6% of patients that lost ER or PR expression 
after breast cancer relapse (47). 
1.6  Genomic risk assessment 
The mentioned clinical markers provide valuable information to accommodate distinction of 
patients at increased risk for breast cancer recurrence and death and therefore candidates for 
postoperative (adjuvant) treatment, such as radiotherapy, chemotherapy, endocrine and 
targeted therapy. Complementary gene-expression signatures, such as OncotypeDx, 
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MammaPrint and Prosigna, can predict breast cancer outcomes and aid selection of patients at 
low genomic risk that are probably not benefited by adjuvant chemotherapy (48-52). The 
gene expression profiles could fill the gap in the unmet need to limit overtreatment with 
adjuvant chemotherapy. The profiles could aid to better identify patients with intermediate 
clinical risk that will not benefit from adjuvant chemotherapy but their value as prognostic 
factors and their clinical usefulness is still undetermined. 
Gene expression profiles can be utilised today for treatment recommendations to avoid 
adjuvant chemotherapy in node negative patients at such low absolute risk that treating them 
would not provide meaningful benefit (53, 54). Of note, access to gene expression analysis 
possibilities around the globe varies gradely. Available data for patients with node positive 
breast cancer are still immature and cannot be largely applied yet. 
1.7  Treatment modalities for early breast cancer 
1.7.1 Surgery 
Surgery upfront versus neoadjuvant chemotherapy 
Multimodal approach is nowadays the pillar for breast cancer management. Surgical excision 
of the primary tumour, by breast conserving surgery or mastectomy prior to application of 
any other treatment modality has long been considered the standard approach to early breast 
cancer. However, the advancement of systemic therapy prior to surgery (neoadjuvant) has 
been practice changing, especially among women with triple negative or HER2 positive 
breast cancer. The choice of whether to recommend neoadjuvant therapy depends on the 
tumour’s molecular subtype, size, lymph node status, comorbidity and the patient’s 
preference. Same chemotherapy regiments administered prior to or after surgery result in 
similar risk for distant recurrence, breast cancer specific and overall survival (55). 
Downsizing the tumour can facilitate surgery and increase the probability to avoid 
mastectomy in larger tumours. Neoadjuvant therapy further provides the possibility of 
prospective in-vivo assessment of treatment effect enabling identification of non-responders 
and potentially tailoring treatment accordingly (56). Eradication of tumour from the breast 
and the lymph nodes, defined as pathological complete response (pCR), is a clinically 
relevant outcome and considered by many to provide a surrogate estimation of better 
outcomes, mainly in HER2 positive and triple negative breast cancer (57). The importance of 
the latter is supported by the reported survival improvement among patients that achieved 
pCR after neoadjuvant therapy, in a pooled analysis (57). Thus, administration of systemic 
breast cancer therapy prior to surgery, allows for selection of the patients that did not respond 
with pCR and will benefit from salvage adjuvant therapy, an assessment that is not be 
possible after primary surgery. The use of neoadjuvant therapy for tumours larger than 2 cm 
in triple negative or HER2 positive breast cancer is currently recommended (34, 58).  
Identifying poor responders and adding capecitabine as salvage adjuvant approach for 
patients with HER2-negative residual tumour after neoadjuvant chemotherapy improved 5-
 10 
year recurrence free survival (absolute gain 6.5%, hazard ratio [HR] 0.70, 95% Confidence 
Interval [CI] 0.53 – 0.92; p=0.01) and 5-year overall survival (absolute gain 5.6%, HR 0.59, 
95% CI 0.39 – 0.90; p=0.01) in a study published by Masuda et al in 2017 (59). Similarly, 
adjuvant treatment with the antibody-drug conjugate trastuzumab-emtansine for patients with 
residual HER2 positive tumour after neoadjuvant trastuzumab and taxane-containing 
chemotherapy, halved the risk for recurrence and led to an absolute risk reduction of 11% 
(60). Additional surrogate methods for identification of patients at increased risk for relapse 
after neoadjuvant therapy such as residual cancer burden and post-neoadjuvant therapy 
staging are under investigation (34, 61).  
Hormone-receptor positive tumours lacking HER2 amplification have thus far not achieved 
as high pCR rates as HER2 positive and triple negative tumours but there are currently on-
going studies examining addition of CDK4/6 inhibitors to endocrine therapy as neoadjuvant 
approach in high-risk luminal B breast cancer. The incidence of objective responses has, thus 
far, not been encouraging but reported trends of improved gene-signature based risk 
estimations hint on potential place of neoadjuvant therapy also in high-risk luminal B breast 
cancer and the issue should therefore be considered unresolved (62-64).  
 
Surgical methods 
Appropriate surgical approach is decided upon tumour-related factors (size) and patient-
related factors (volume of the breast, patient’s preference, pregnancy). Up to 90% of breast 
cancer recurrences are local recurrences after breast conserving surgery but postoperative 
radiotherapy has been shown to reduce the risk of local or distant recurrence by half and 
provide a relative reduction of breast cancer mortality by 18% (Risk Ratio [RR] 0.82, 95% CI 
0.75 – 0.90; p<0.001) (65, 66). Recent retrospective studies support superior breast cancer 
specific and overall survival after breast conserving surgery and radiotherapy than 
mastectomy alone, in small, node negative tumours (67, 68). However, intrinsic limitations of 
retrospective studies and obvious bias by selection of patients with more aggressive tumours 
to undergo mastectomy, call for caution in the interpretation of the results.  
Regional axillary lymph nodes are usually treated by sentinel node biopsy and/or axillary 
dissection. Sentinel node biopsy has negligible side effects and is used as a prognostic marker 
to de-escalate axillary surgery in patients with negative sentinel node biopsy. Addition of 
axillary dissection in sentinel node negative breast cancer does not improve survival and it is 
hence not recommended (69). On the contrary, it can aggravate morbidity, such as 
lymphedema (70). Moreover, axillary dissection has so far been the standard praxis in 
sentinel node positive disease, however recent studies demonstrate that, for selected patients, 
sentinel node biopsy alone is not inferior to complementary axillary surgery. It is, thus, 
considered safe to refrain axillary dissection among patients with lymph node metastasis up 
to 2 cm (69, 71, 72). The timing of sentinel node biopsy and extend of axillary surgery in the 
context of neoadjuvant therapy is under investigation. 
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Breast reconstruction with implant or autologous tissue after mastectomy is considered safe 
regarding oncological outcomes and can be performed immediately or delayed depending of 
the tumour characteristics and the patient’s preference (73-77). Direct reconstruction after 
inflammatory breast cancer is though discouraged and delayed reconstruction should also be 
considered in the case of locally advanced breast cancer with skin or thoracic wall 
involvement. 
 
1.7.2 Radiotherapy 
Since breast conserving surgery became the surgical method of choice for small breast 
tumours, there was a concern on the risk of local recurrence. However, administration of 
adjuvant radiotherapy on the remaining breast evens out increased risk of recurrence after 
breast conserving surgery (65, 66). In absolute numbers, adjuvant radiotherapy after breast 
conserving surgery reduced 10-year risk of recurrence by 15.7% and 15-year risk for breast 
cancer death by 3.8% according to the Early Breast Cancer Trialists’ Collaborate Group 
(EBCTCG) report in 2011 (65). Efficacy of radiotherapy is even more prominent among 
women with lymph node tumour burden, associated to an absolute reduction of 10-year risk 
for recurrence by 21.2% (65). Nevertheless, according to randomised and non-randomised 
data, omitting radiotherapy in women older than 70 years with small, hormone receptor 
positive breast cancer does not lead to worse overall or disease-free survival and can be a safe 
option, provided adjuvant endocrine therapy is administered (78-80).  
Addition of boost to the tumour bed in the radiotherapy plan, following breast conserving 
surgery, does not improve breast cancer survival but improves local control. Administration 
of boost is correlated to an absolute reduction of the 20-year cumulative incidence of 
ipsilateral breast cancer by 4.4% (16.4% versus 12.0% in no boost group) (81).  The absolute 
risk reduction is more prominent among younger patients (absolute gain 11.6% for those 
under 40 years and 5.9% for those 41-50 years) and administration of boost on the tumour 
bed is thus deemed clinically relevant to be provided to women younger than age 50. 
Importantly, boost significantly increases severe fibrosis in corresponding levels; 1.8% in no 
boost group compared to 5.2% in the boost group (p<0.0001) (81).  
Another important aspect is the place of adjuvant radiotherapy after mastectomy. A large 
meta-analysis from the EBCTCG in 2014 did not demonstrate significant improvement of the 
risk for loco-regional recurrence after 10 years (RR 1.06, 95% CI 0.76 – 1.48; p>0.1) or 20-
year risk for breast cancer mortality (RR 1.18, 95% CI 0.89 – 1.55; p>0.1) after adjuvant 
radiotherapy of the chest wall, amid women that had undergone mastectomy and axillary 
dissection. On the contrary, adjuvant radiotherapy in this setting increased the risk for overall 
mortality (RR 1.23, 95% CI 1.02 – 1.49; 2p=0.03) (82). However, women with lymph node 
positive disease had a significant benefit from adjuvant radiotherapy after mastectomy, both 
in terms of 10-year breast cancer recurrence and 20-year breast cancer specific survival; 
absolute gain of 10.6% and 8.1% respectively (82). 
Dose per fraction and number of fractions in adjuvant breast cancer radiotherapy has been 
changing over time. Hypofractionated radiotherapy (nowadays 2.65 Gy divided in 15 
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fractions) has been shown of equal biological efficacy as conventional fractionation with 50 
Gy divided by 2 Gy fractions (83). In addition, shorter treatment duration has been 
demonstrated to be beneficial in terms of lower risk for skin toxicity and telangiectasia but 
impact on the risk for long-term cardiotoxicity and lung-fibrosis is unknown (83).  
 
1.7.3 Chemotherapy 
As abovementioned, chemotherapy in early breast cancer, can be delivered preoperatively 
(neoadjuvant) or as additional treatment after primary surgery (adjuvant chemotherapy). 
Historically, adjuvant chemotherapy was offered to patients with node positive breast cancer. 
However, the development of different predictive and prognostic biomarkers has led to a 
more complex assessment of relapse risk and chemo-/endocrine-sensitivity prior to treatment 
decisions on individual level. A large meta-analysis of the EBCTCG on individual patient 
data from 100 000 women revealed reduction of breast cancer mortality by one third after 
adjuvant chemotherapy (84).  
Initially the combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) 
reduced breast cancer mortality at 20 years by one fourth, compared to no adjuvant 
chemotherapy (85). Addition of anthracyclines compared to no adjuvant chemotherapy 
decreased relative risk for breast cancer mortality by 21% (absolute risk reduction at 10 years 
6.5%) (84). The benefit of anthracyclines persisted regardless age, nodal involvement, ER 
status, tumour size and differentiation (84). Moreover, a higher cumulative dose of 
anthracycline-containing regimens was shown to be superior to CMF by reducing the relative 
risk of 10-year breast cancer mortality by one fifth (absolute risk reduction 4.1%) (84).  
Further on, addition of taxanes improved relative risk for breast cancer mortality by 13%. 
Anthracyclines and taxanes given in sequence were superior in terms of breast cancer 
recurrence compared to concomitant administration, with an absolute reduction of recurrence 
by 3.2% (RR 0.87, 95% CI 0.80 – 0.94; p<0·001) (84). 
There is a strong biological rationale for intensification of chemotherapy regimens. 
Increasing dose or shortening the treatment interval (dose-dense chemotherapy), can 
potentiate treatment effect and produce better cancer-related outcomes. It is generally 
hypothesised that intensifying chemotherapy dose would increase the number of tumour cells 
killed and shortening of the treatment interval would enhance treatment effect by providing 
less time for the recovery of the tumour-cells. This is supported by different hypotheses with 
the Norton-Simon hypothesis having a central role. Simon and Norton suggested that 
‘chemotherapy results in a rate of regression of tumour volume that is proportional to the rate 
of growth for an unperturbed tumour of that size' (86). In addition, Norton suggests that 
reduction of the tumour volume by chemotherapy can lead to faster tumour re-growth 
between cycles, since small tumours are considered to grow faster than larger tumours (87). 
Another hypothesis supports that drug-resistance develops spontaneously after administration 
of chemotherapy and as such, early introduction of intensive therapy and considering 
alternating regimens (such as anthracyclines and taxanes in sequence) can further improve 
efficacy of administered therapy (88).  
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In accordance with these hypotheses, the individual patient data based meta-analysis of 
EBCTCG published in 2019 reported a benefit in breast cancer mortality with dose-intense 
anthracycline and taxanes adjuvant chemotherapy compared to standard chemotherapy (89). 
In particular, when the same agents were administered but with shorter interval (two weeks 
versus three weeks), 10-year recurrence of any type was reduced in absolute numbers by 
4.3% (24% versus 28.3%) and breast cancer survival by 2.8% (16.8% versus 19.6%). This 
was translated in a relative risk reduction for recurrence by 17% (RR 0.83, 95% CI 0.76 – 
0.91) and for breast cancer mortality by 14% (RR 0.86, 95% CI 0.77 – 0.96). Non-breast 
cancer mortality did not increase with intensive chemotherapy and combined with the overall 
survival improvement, suggests that the survival benefit is solely due to reduced breast cancer 
mortality (89).  
Despite the clear benefit from increasing dose intensity of anthracyclines and taxanes, 
increasing cyclophosphamide dose intensity and/or cumulative dose in the adjuvant setting in 
the NSABP B22 and B25 trials, did not correspond to improved disease-free or overall 
survival (90, 91). The phase III PANTHER trial, further discussed in detail in the current 
thesis, compared standard dose 3-weekly chemotherapy with tailored dose dense 
chemotherapy (92). A fundamental difference between the PANTHER and the B22 and B25 
trials is the protocol pre-defined dose escalation according to toxicity of the anthracycline, 
taxanes and cyclophosphamide doses. Thus, cyclophosphamide escalation was not performed 
to all participants of the PANTHER trial but it was reserved for those probably undertreated 
according to standard therapy. 
Notably, the relative benefit from increased dose intensity in the EBCTCG meta-analysis 
persisted regardless patient and tumour characteristics; age, ER status, nodal status, HER2 
status, tumour size, Ki67 and grade (89). The proportional outcomes in ER positive and ER 
negative disease imply long-term survival in ER positive disease is not uniquely related to 
adjuvant endocrine therapy but is also an aftereffect of adjuvant chemotherapy. Importantly, 
increased dose-intensity was not compromised by increased toxicity; deaths from 
cardiovascular disease, acute myeloid leukaemia or other malignancy did not differ from 
standard chemotherapy schedules. 
Relative dose intensity (RDI) of chemotherapy defined as the ratio of delivered dose intensity 
to the standard dose intensity is directly related to cancer-specific outcomes in both early and 
metastatic setting. In particular, delivery of RDI ≥ 85% in early breast cancer has been related 
to improved breast-cancer specific and overall survival (93, 94). Even in the metastatic 
setting, increased RDI is related to improved objective response (95). Current practice usually 
relies dosing on the body surface area, not taking into account inter-patient variations in 
pharmacogenomics and pharmacodynamics (96). However, a recent publication suggests that 
excess adiposity can lead to lower RDI and worse breast cancer survival (97). In addition, 
individually tailoring chemotherapy dose based on haematological toxicity improved 5-year 
event free survival (RR 0.79, 95% CI 0.63 – 0.99; p=0.04) even though the benefit in overall 
survival did not reach significance (92). Such observations strengthen the need for 
development of improved methods for individualised dose calculation based on the 
intrapersonal unique pharmacodynamic and pharmacokinetic characteristics. 
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1.7.4 Anti-HER2 therapy  
The discovery of the HER2/neu as oncogene related to breast cancer in 1985 has 
revolutionised care and outcomes for this particular subgroup (98). Shortly after, in 1987, 
Slamon et al reported correlation of HER2/neu amplification and worse breast cancer 
prognosis with the contemporary treatment approach (99). The subsequent development of 
the humanized monoclonal antibody trastuzumab, and later on other anti-HER2 agents, led to 
a cascade-like evolution of the management of HER2 amplified breast cancer and constitutes 
a brilliant example of translational research directly impacting clinical praxis and benefiting 
the patients. In the first reported study, trastuzumab added to chemotherapy improved 
objective response and time to progression and, overwhelmingly, improved survival with a 
20% reduction in risk of death among heavily pre-treated women with metastatic, HER2 
amplified, breast cancer (100). Trastuzumab efficacy is potentiated by concomitant 
chemotherapy treatment, as already demonstrated in early trastuzumab trials in metastatic 
breast cancer, with reported response rate of trastuzumab in combination with cisplatin 
superior to trastuzumab alone (101). Synergistic effect was also present in combination with 
taxanes, anthracyclines and cyclophosphamide and currently there is a recommendation for 
administration of anti-HER2 therapy in combination with chemotherapy or at least to initiate 
with concomitant therapy (100, 102). 
Following the unequivocal success of trastuzumab, several other anti-HER2 agents were 
developed. The antibody-drug conjugate T-DM1, that combines trastuzumab with the 
chemotherapeutic agent emtansine, the recombinant, humanised, monoclonal antibody 
pertuzumab and the tyrosine kinase inhibitors lapatinib and neratinib are the ones currently 
available after approval by the competent authorities. 
In the context of neoadjuvant therapy for HER2 positive breast cancer, addition of 
pertuzumab to neoadjuvant chemotherapy and trastuzumab (with trastuzumab continuing 
even postoperatively for total treatment duration one year) in the NeoSphere trial, improved 
complete pathological response and five-year survival (103). Even though difference in 
event-free (EFS) and overall survival (OS) was not statistically significant (HR EFS 0.81, 
95% CI 0.52 – 1.26 and HR OS 0.72, 95% CI 0.41 – 1.27), neoadjuvant administration of 
lapatinib in combination with trastuzumab in the NeoALTTO trial led to numerically less 
events at six years follow-up compared to trastuzumab alone (85% versus 79% respectively) 
and demonstrated the survival impact of pathologic complete response after neoadjuvant 
therapy in HER2 positive breast cancer (104). Another neoadjuvant trial (KRISTINE) 
demonstrated substantial benefit from dual blockade but it also underscored the value of 
combination of anti-HER2 treatments with conventional chemotherapy (105). The TRAIN-2 
study provided support for the use of non-anthracycline regimens during neoadjuvant therapy 
for HER2 positive breast cancer; an essential step to reduce risk for cardiotoxicity (105, 106). 
Hence, dual HER2 blockage (pertuzumab and trastuzumab) with backbone chemotherapy is 
presently standard of care in the neoadjuvant setting for HER2 amplified breast cancer. 
In the adjuvant setting, 5099 individuals were enrolled in the Herceptin Adjuvant (HERA) 
trial investigating one and two years’ treatment duration that demonstrated superiority of one-
year trastuzumab compared to control with relatively equal effect for ER positive and ER 
negative breast cancer. Disease free survival was improved by 24% (HR 0.76, 95% CI 0.68 – 
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0.86), the risk of death was reduced by 26% (HR 0.74, 95% CI 0.64 – 0.86) and 63% were 
breast cancer free at 10 years (107). The value of adjuvant trastuzumab was further 
investigated and a Cochrane review including eight studies revealed improved disease free 
survival by 40% with the administration of trastuzumab in HER2 positive breast cancer 
(108). Despite the initial hypothesis that lapatinib would have better efficacy than 
trastuzumab, the head to head comparison of the two as adjuvant therapies in the ALTTO 
trial demonstrated 34% worse DFS with lapatinib compared to trastuzumab as single anti-
HER2 therapies, at the updated 4.5 years median follow-up (HR 1.34, 95% CI 1.13 – 1.60) 
(109). Adding pertuzumab for the whole duration of adjuvant trastuzumab (1 year) did not 
benefit the 3-year invasive-disease free survival for node negative tumours but was superior 
among patients with positive lymph nodes (HR 0.77, 95% CI 0.62 – 0.96; p=0.64) (110).   
The considerably arbitrary one-year treatment duration of adjuvant trastuzumab has been 
challenged in both directions. The HERA trial failed to show any survival benefit from 
increasing treatment duration to two years (107). Shorter duration of adjuvant trastuzumab, 
such as 9 weeks or 6 months, has also been tested due to trends of higher incidence of cardiac 
events with longer trastuzumab duration. Most of the shorter duration studies have a non-
inferiority design and thus far only the PERSEPHONE trial (6 months versus one-year 
trastuzumab) has fulfilled non-inferiority criteria with an absolute benefit in disease-free 
survival (DFS) in the longer duration of 0.4% (111-113). Four other trials investigating 
shorter intervals (SOLD, Short-HER, PHARE and HORG) have shown gains in DFS with 
one-year trastuzumab in the range of 2-3% (114-117). To conclude, one-year trastuzumab 
treatment, including a chemotherapy part with taxane-including regimens, remains the 
standard of care, despite concerns for trade-offs in cardiac events (111-116, 118). 
Moreover, as aforementioned, addition of T-DM1 as adjuvant therapy halved the risk of 
death from invasive disease for patients not achieving complete pathological response after 
neoadjuvant therapy, corresponding to an absolute benefit of 11% (HR 0.50, 95% CI 0.39 – 
0.64) (60). As a result, adjuvant salvage therapy with T-DM1 is currently recommended for 
patients with considerable tumour burden at surgery following neoadjuvant therapy for HER2 
amplified breast cancer.    
Even in the metastatic setting, dual blockade with pertuzumab and trastuzumab in 
combination with docetaxel, substantially improved prognosis by improving overall survival 
with 15.7 months and median progression-free survival by half a year (119). Backbone 
chemotherapy in combination with pertuzumab and trastuzumab is today the treatment of 
choice for first line therapy in HER2 positive metastatic breast cancer and the rest of the 
abovementioned anti-HER2 agents further enrich our armamentarium and prolong survival. 
Development in the care of metastatic HER2 positive breast cancer is rapid and continuous, 
with more drugs such as tucatinib and deruxtecan in the pipeline (120-122).  
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1.7.5 Endocrine therapy 
ER and/or PR expression is both a prognostic marker of improved breast cancer survival and 
predictive of benefit from endocrine therapy with reduction of breast cancer relapse and 
survival (123). Tamoxifen is a selective oestrogen receptor modulator (SERM) and can act as 
oestrogen antagonist in breast tissue but as oestrogen agonist in, for example, uterus. After 
menopause, oestrogen production is limited to peripheral tissues through aromatisation of 
androstendione to estradiol. The aromatase inhibitors (AI) letrozole, anastrozole and 
exemestane inhibit this process leading to reduction of estradiol levels. 
Five years adjuvant tamoxifen among patients with ER positive early breast cancer improved 
10-year overall survival by 6% compared to two years of tamoxifen; 80% versus 74% 
respectively and reduced breast cancer mortality by 30% during the first 15 years following 
breast cancer diagnosis (RR 0.70, 95% CI 0.64 – 0.75; p<0.001) (124) (125).  
The effect of ovarian ablation alone (by gonadotropin-releasing hormone agonists [GnRHa], 
surgery or radiation) is less prominent among premenopausal women that have received 
chemotherapy, probably due to early ovarian function suppression secondary to 
chemotherapy-induced amenorrhea (CIA) but addition of GnRHa to tamoxifen demonstrates 
a relative risk reduction for breast cancer death by 15% (123, 126, 127). Benefit in overall 
survival from addition of GnRHa to tamoxifen is mostly for women with high-risk breast 
cancer that remain premenopausal after adjuvant chemotherapy, and this combination is 
recommended for the specific population (128). A jointed analysis of the Suppression of 
Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT) revealed 
improved disease-free survival by an absolute difference of 4% with ovarian suppression and 
AI compared to ovarian suppression and tamoxifen (HR 0.77; 95% CI, 0.67 – 0.9; p<0.001) 
but no survival benefit (128). On the other hand, the ABCSG-12 trial reported lack of benefit 
from AI and GnRHa compared to tamoxifen and GnRHa and increased risk of death from 
any cause (HR 1.63, 95% CI 1.05 – 1.45) (129, 130). The lack of survival benefit in the 
SOFT/TEXT trials, the reported worse survival from GnRHa and AI versus GnRHa and 
tamoxifen in the ABCSG-12 trial together with reports on hormonal escape during GnRHa 
treatment advise for monitoring of estradiol levels to ensure complete ovarian suppression 
when AI in combination with GnRHa is offered to premenopausal women (131). Sufficient 
ovarian suppression during concurrent therapy with AI is of paramount importance and has 
been debated in a dedicated article (131). 
In postmenopausal women with early breast cancer, 5 years of AI further improved breast 
cancer mortality (RR=0·86, 95% CI 0.80 – 0.94; p=0·0005) even thought the benefit on 
breast cancer recurrence was only present during the treatment period (132, 133). Even 
switching to AI after 2-3 years tamoxifen, with total endocrine therapy duration for 5 years 
showed slightly increased breast cancer outcomes compared to 5 years tamoxifen alone 
(132). 
A minimum of five years adjuvant endocrine therapy has been the standard recommendation 
for a few decades. However, almost half of the recurrences happen after the first 5 years of 
follow-up and the risk of breast cancer distant-recurrence among women with hormone 
receptor positive early breast cancer can persist up to 20 years, depending on tumour burden 
and grade (134, 135). Extending tamoxifen treatment to 10 years in the Adjuvant Tamoxifen 
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Longer Against Shorter (ATLAS) and adjuvant Tamoxifen To offer more (aTTom) trials 
demonstrated further improvement of the risk for breast cancer recurrence and breast cancer 
specific mortality (136, 137). In the ATLAS trial, the benefit of 10 years tamoxifen became 
more obvious after year 10 for both risk for recurrence (RR 0.75, 95% CI 0.62 – 0.90) and 
breast cancer mortality (RR 0.71, 95% CI 0.58 – 0.88) (136). In line with these results, longer 
tamoxifen duration in the aTTom trial had a significant impact on breast cancer recurrence 
after treatment year 7 (RR during years 7-9: 0.84, 95% CI 0.73 – 0.95) and breast cancer 
mortality after year 10 (RR 0.77, 95% CI 0.64 – 0.92) (137).  
Similarly, in the MA.17 trial, extended endocrine therapy with the aromatase inhibitor 
letrozole after 5 years of tamoxifen improved risk for recurrence by 42% and among women 
with lymph node positive breast cancer it also demonstrated benefit in overall survival (HR 
0.61, 95% CI 0.38 – 0.98; p=0.04) (138). Most valuable effect of prolonged AI appears to be 
after 5 years tamoxifen. Extended treatment with additional five years of AI for patients 
already treated with AI for five years demonstrated reduced risk for breast cancer recurrence 
but this was not translated to better breast cancer specific or overall survival (139-141). 
However, there is a significant heterogeneity among patients identified as high-risk and 
therefore careful selection of the candidates for prolonged endocrine therapy is warranted 
(51). In summary, based on the presented results, prolonged endocrine therapy for 10 years is 
currently standard of care for high-risk breast cancer.  
 
1.7.6 Bisphosphonates  
Despite indications of benefit from adjuvant bisphosphonates in premenopausal women in the 
ABCSG-12 study, the large meta-analysis of EBCTCG on the efficacy of 2-5 years treatment 
with bisphosphonates in 2015, reported benefit in overall breast cancer related outcomes only 
in postmenopausal women (129, 142). The specific group benefited by a relative risk 
reduction of distant recurrence and breast cancer death by 18% (RR 0.82, 95% CI 0.74 – 0.92 
and 95% CI 0.73 – 0.93, respectively) and improvement of the risk for recurrence in the bone 
by 28% (RR 0.72, 95% CI 0.60 – 0.86) (142). Type of administered bisphosphonate, 
treatment schedule, administered chemotherapy, and tumour burden did not affect efficacy 
(142). A subsequent Cochrane meta-analysis added further data on survival benefit of 
bisphosphonates administration in postmenopausal women (HR 0.77, 95% CI 0.66 – 0.90; 
p=0.001) and, so far, lack of such in premenopausal women (143).  
Denosumab, a fully human monoclonal antibody that inhibits osteoclast activity, is widely 
used for the treatment of osteoporosis. In terms of breast cancer efficacy, adjuvant 
administration of denosumab has been shown superior to bisphosphonates in terms of 
skeletal-related events (RR 0.78, 0.72 – 0.85; p< 0.001) (143). Denosumab led to significant 
gain in disease-free survival compared to placebo in the ABCSG-18 study whereas the, also 
placebo controlled, study D-CARE reported no benefit in disease-free survival or risk for 
bone metastasis from denosumab (144, 145). In the context of osteoporosis, concerns have 
been raised on optimal treatment duration and management after treatment discontinuation 
due to evidence reporting harmful rebound effect and increased bone fractures following 
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denosumab cessation (146). To stipulate the impact of denosumab discontinuation on breast 
cancer related outcomes is far from simple but the available data should raise awareness. 
Adjuvant bisphosphonates are considered by many as a way to partly counterpart increased 
osteoporosis risk related to long-term aromatase inhibitors administration. It is though unclear 
whether a potential rebound effect after denosumab discontinuation can aggravate bone 
health among these patients.  
 
1.7.7 Immunotherapy 
Immune checkpoint inhibitors have transformed management and survival of several solid 
tumours such as lung cancer, malignant melanoma and renal cancer. In breast cancer, the leap 
has not been equally impressive. Expression of programmed death ligand 1 (PD-L1) on the 
immune cells infiltrating TNBC tumours impedes the immune response against the tumour 
and therefore constitutes a reasonable therapeutic target. Despite that, efficacy of immune 
checkpoint has been, thus far, shown mostly in metastatic TNBC. 
Neoadjuvant pembrolizumab, a monoclonal antibody that inhibits interaction of programmed 
death-1 (PD-1) receptor with PD-L1 or PD-L2, in combination with chemotherapy led to a 
higher rate of pathologic complete response rate by 13% compared to chemotherapy alone, a 
statistically significant improvement (147). Pembrolizumab treatment effect was consistent, 
regardless PD-L1 receptor status. 
Atezolizumab, a selective PD-L1 antagonist, in combination with nab-paclitaxel did not 
improve overall survival among patients with metastatic or unresectable TNBC compared to 
nab-paclitaxel alone in the intention-to-treat analysis (HR 0.86, 95% CI 0.72 – 1.02) (148). 
Although, stratified exploratory analysis revealed overall survival benefit of atezolizumab, 
compared with placebo, in the PD-L1 positive group (HR 0.71, 95% CI 0.54 – 0.94) (148). 
Early phase trials also suggest pembrolizumab efficacy in the metastatic setting as 
monotherapy or in combination with other therapies; both for TNBC but also for other breast 
cancer subtypes suggesting there still may be place for immunotherapy in both early and 
metastatic breast cancer (149-151).  
 
1.8 Common toxicity of breast cancer therapies 
1.8.1 Surgery 
Development in breast cancer surgery has been towards minimising surgical intervention and 
shortening hospitalisation time. A Danish study reported, in a health care system similar to 
the Swedish, that 72% of all breast cancer operations were performed as outpatient with a rate 
of wound-related re-admission within 30 days following surgery as low as 2% (152). Up to 
10% of the patients can experience any type of short-term complication across different 
surgical approaches (153). The patients should be informed of potential complications such as 
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hematoma or seroma requiring drainage, infection and complications related to the flap or 
expander used in reconstructions.  
Another known complication of breast cancer surgery is lymphedema. Lymphedema can 
augment after axillary lymph node dissection and/or radiotherapy and can present shortly or 
long-time after surgery. For example, long-term follow-up of the IBCSG 23-01 trial revealed 
that 13% of the patients that underwent axillary lymph node dissection (n=447) developed 
lymphedema of any grade, about one in five developed sensory neuropathy (19%) and almost 
one in ten (9%) motor neuropathy (154). Similarly, McLaughlin et al reported incidence of 
lymphedema in 16% of patients with axillary surgery compared to 5% of those with sentinel 
node biopsy (155). These results are in concordance with the AMAROS study where twice as 
many patients developed lymphedema, defined as increase of arm circumference 10% or 
above, five years after axillary surgery compared to axillary radiotherapy alone (13% versus 
6%, p<0.001) (72).   
Beyond physical complications, breast cancer surgery can have psychological downsides 
such as those related to alteration of the person’s perceived body image. The cosmetic result 
is often considered the major advantage of breast conserving surgery and one would expect it 
reduced psychological impact emanating from altered body image perception. Data is 
however inconsistent and body image perception appears to be similar between patients 
undergoing breast conserving surgery and radiotherapy or mastectomy with reconstruction at 
two years following surgery (156). Interestingly, at the same follow-up, patients that 
underwent mastectomy alone report better body image compared to patients with mastectomy 
and direct reconstruction (156). 
 
1.8.2 Radiotherapy 
Side effects of radiotherapy are generally considered to be limited to the irradiated area and 
the surrounding tissues, although some data suggest that it could also increase the risk for 
marrow neoplasms (157). Lungs and heart are organs of particular interest in the adjuvant 
radiotherapy of breast cancer. Most common short-term toxicity of radiotherapy of the breast, 
with or without regional lymph nodes, is skin toxicity in the irradiated area and it can vary 
from erythema to moist desquamation (158). Radiation pneumonitis is less common and can 
occur as acute side effect or as long-term toxicity in the form of lung fibrosis (159, 160). 
Ionizing radiation can injure all the anatomical structures of the heart and the large vessels 
through inflammation and fibrosis liable for a range of long-term conditions such as 
pericarditis, valvular dysfunction, cardiomyopathy and coronary artery disease. As expected, 
in the case of breast cancer, risk for long-term cardiovascular side effects is increased in left-
sided breast cancer and history of cardiac disease. There is a clear association between 
distribution of stenosis in coronary arteries and the radiotherapy field (161).  
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Administration of radiotherapy has been related to increased risk of secondary cancer, such as 
lung cancer, and non-breast cancer mortality secondary to cardiac disease (162). A recent 
publication reported cumulative incidence of radiation-associated breast angiosarcoma after 
radiotherapy for breast cancer to 0.1% with increased risk for older patients and those 
receiving radiotherapy after breast conserving surgery (163). Long-term smoking is related to 
increased risk for lung cancer (4% versus 0.3% for non-smokers) and cardiovascular 
mortality (1% versus 0.3 %), according to a meta-analysis based on individual data from 
breast cancer patients treated with modern radiotherapy techniques (162).  
The evolution of the radiotherapy techniques for treatment planning and delivery have led to 
sharp reduction in the incidence of acute pericarditis, however chronic pericarditis still 
develops up to 12% at 30 years after chest irradiation (164, 165).  
Early radiotherapy trials using older techniques showed excess mortality related to reasons 
other than breast cancer, leading to the conclusion that radiotherapy-related side effects can 
even out benefit on breast cancer mortality (166). On the other hand, a meta-analysis by the 
EBCTC,G including 13 500 women, reported no increase in 10-year non-breast cancer 
mortality in more recent (1989 – 2003) radiotherapy versus no radiotherapy trials; 5% versus 
4.8% respectively (167). One can hypothesise, that newer technology, such as, for example, 
gating and coordination with breathing variation will further reduce radiation to the heart and 
lungs during breast and chest wall radiotherapy, with or without node irradiation. 
Nonetheless, potential confounding from radiotherapy needs to be taken into consideration 
when assessing potential cardiotoxic effects of systemic therapies, particularly in left-sided 
breast cancer. 
 
1.8.3 Chemotherapy 
Chemotherapy administered as adjuvant, neoadjuvant or palliative therapy in breast cancer 
can cause short-term and long-term toxicity. The frequency, character and severity of the 
related toxicity usually depend primarily on the type of regimens used and the dosing 
schedules.  
Adjuvant breast cancer chemotherapy-related short-term toxicity develops during 
chemotherapy and particularly anthracycline-based regimens tend to cause more short-term 
toxicity than non-anthracycline ones (168). The most commonly described symptoms are 
fatigue, nausea and emesis, alopecia, myelosuppression and mucositis. The reported 
frequency of nausea has been varying but, nowadays, it is expected to be lower due to the 
wide adaptation of primary prophylaxis with serotonin antagonists (such as ondansetron and 
palonosetron) and neurokinin-1 receptor antagonist (aprepitant) (169). Specific chemotherapy 
regimens such as taxanes can also cause peripheral neuropathy up to 22% and myalgia (168, 
170).  
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Long-term toxicity can occur during the course of chemotherapy and become persistent, but it 
can also develop long time after chemotherapy completion. Common late toxicities can 
include cardiovascular disease, cardiomyopathy with or without heart failure, secondary 
malignancies and chemotherapy-induced amenorrhea and subsequent transient or permanent 
premature ovarian insufficiency and infertility (168).  The latter has also been associated with 
long-term increased risk for osteoporosis and cardiovascular disease (171). Early studies have 
also reported varying frequency of weight gain. Up to 83% of women receiving adjuvant 
chemotherapy gain weight, especially premenopausal women in general or premenopausal 
women that develop chemotherapy-related ovarian suppression (168, 172). 
Cognitive dysfunction has been observed both during and after adjuvant chemotherapy for 
breast cancer. Objective and subjective memory impairment have been reported and even 
though the severity of daily memory lapses may not differ from healthy individuals, they 
indeed have a bearing on the quality of life of the individual (173, 174). A common 
parameter between many reported longitudinal studies is the presence of subjective cognitive 
impairment and lack of objective findings, questioning the mere existence of a direct 
neurophysiological damage from chemotherapy. However, the nature of the cognitive 
changes, other concomitant treatment and methodological hurdles, have caused large 
heterogeneity between the studies and hamper conclusions. Neuroimaging studies have 
reported structural and functional differences between breast cancer patients and controls 
suggesting increased effort and overcompensation being the source of lack of objective 
findings despite the patients’ experience of failing cognitive function (175). Although 
existence of cognitive dysfunction during and after chemotherapy is reported, it is more likely 
the result of other psychoneurological conditions such as fatigue and endocrine alterations 
due to endocrine therapy, rather than direct toxic effect of chemotherapy (176-178).  
Secondary haematological malignancies such as acute myeloid leukaemia/myelodysplastic 
syndrome (AML/MDS) have also been reported as unwanted events after adjuvant breast 
cancer chemotherapy. However, an analysis by Praga et al, reported that patients treated with 
commonly used anthracycline and cyclophosphamide doses (epirubicin ≤ 720 mg/m2 and 
cyclophosphamide ≤ 6300 mg/m2) had reported cumulative probability of AML/MDS after 8 
years of follow-up as low as 0.37% (95% CI 0.13 – 0.61%) (179). On the contrary, high 
cumulative epirubicin and cyclophosphamide dose significantly increased cumulative 
probability of AML/MDS at 8 years to 4.97% (95% CI 2.06 – 7.87) (179). Cumulative 
epirubicin dose of more that 720 mg/m2 was related to an almost 7-fold increased risk, 
compared to lower cumulative doses (HR 6.80, 95% CI 2.86 – 16.13) (179). Similarly, the 
EBCTCG also reported incidence of less then 1% in their large meta-analysis on 
polychemotherapy benefit in early breast cancer (84). The mentioned meta-analysis based on 
individual patient data from 100 000 women that participated in >100 clinical trials, actually 
revealed that adjuvant chemotherapy did not lead to excess mortality. On the contrary, overall 
mortality was in accordance with breast cancer specific mortality (84).  
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Tailored, dose-dense chemotherapy results in higher chemotherapy doses and, as expected, 
higher acute toxicity but does not exaggerate long-term cardiotoxicity or haematological 
toxicity (92, 96). In the EBCTCG meta-analysis from 2019, rates of death secondary to 
AML/MDS were not affected by increased chemotherapy dose intensity; 33 events with 
AML/MDS were reported in the dose-intensive group (n=18623) and 17 in the standard 
schedules (n=18750) (89). In the PANTHER phase III trial patients received not only shorter 
chemotherapy intervals (2 weeks) but also individualised dose escalation (92). Incidence of 
AML/MDS was consistently low, with three patients in the tailored and dose dense treatment 
group (n=1001) compared to two patients in the standard chemotherapy group (n=999) (92). 
Cardiotoxicity, neutropenia and chemotherapy-induced amenorrhea are related to the current 
thesis and will be discussed separately. 
 
1.8.4 Endocrine therapy 
Commonly reported side effects of endocrine therapy include hot flashes (30-40%), fatigue, 
mood disturbances, sexual dysfunction and musculoskeletal pain, although tamoxifen and AIs 
can exhibit differential side effects (180). Tamoxifen has been related to slight increase of 
risk for endometrial cancer (1.2% versus 0.4% in the aromatase inhibitor group), ischemic 
cerebrovascular events and thromboembolic episodes, whereas AIs increase the risk for 
osteoporosis, bone fractures (absolute excess 2.7%) and arthralgia (132, 181).  
Interestingly, placebo controlled trials in the adjuvant setting report similar incidence of 
symptoms among patients receiving endocrine therapy and placebo. In the NSABP B-42 trial 
investigating prolonged letrozole treatment versus placebo after 5 years endocrine therapy in 
postmenopausal women, incidence of arthralgia and back pain did not differ between the 
placebo and the letrozole group; both adverse events were reported around 2% in both groups 
(182). Even other endocrine-therapy related side effects such as hot flashes, myalgia and 
depression were equally rare (182). Similarly, the MA-12 trial comparing 5 years tamoxifen 
versus placebo among premenopausal women reported indifferent frequency of hot flashes 
(82% vs. 81%), arthralgia (23% vs. 29%), myalgia (17% vs. 19%), headache (12% vs. 15%), 
and vaginitis/vaginal fibrosis (27% vs. 20%) (183). Notwithstanding different trials and drugs 
administered, the incidence of side effects in the premenopausal women of the MA-12 trial is 
clearly higher than the postmenopausal women enrolled in the NSABP-12. It is therefore 
highly relevant to question whether the reported side effects can be genuinely ascribed solely 
to adjuvant endocrine therapy or could be related to other reasons, considering the 
concordance in the reported incidences between both patients treated with active agents and 
placebo. 
Furthermore, concerns have been raised on potential cardiovascular negative effects of AI 
with two recent reviews reporting contradicting results (184, 185). It is speculated that excess 
cardiac events in the aromatase inhibitor group could depend on positive effect of tamoxifen 
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and not real harmful effect of AI. Figure 6 summarises common toxicity in the different 
treatment modalities. 
 
 
Figure 6. Common toxicities related to the different breast cancer treatment modalities. *Related to 
tamoxifen. CIA: Chemotherapy-induced amenorrhea, CINV: Chemotherapy-induced nausea and vomiting, 
CIPN: Chemotherapy-induced peripheral neuropathy, MSC: musculoskeletal  
 
1.9 Breast cancer chemotherapy-related cardiotoxicity 
There is a perplex relationship between breast cancer and heart disease with shared risk 
factors such as lack of physical exercise, smoking, obesity and old age, consisting a common 
denominator. Additionally, it was early established that breast cancer therapy could have 
potentially detrimental effects on the cardiovascular system. With an expected 5-year breast 
cancer survival of up to 90% (with regional variations), there is an increased prevalence of 
breast cancer survivors at risk for developing cardiovascular disease or heart failure after 
treatment for early breast cancer. Table 2, summarises risk factors and onset of cardiotoxicity 
for the most commonly used chemotherapeutic and targeted agents in early breast cancer 
treatment. 
Compared to age-matched controls, women with breast cancer history have lower risk of 
coronary revascularisation but similar risk for cardiovascular death (186). Importantly, the 
presence of cardiovascular risk factors is the drive to greater risk for cardiovascular disease 
and mortality, regardless breast cancer history (186). The 10-year-risk of cardiovascular 
disease is equal or higher than breast cancer relapse risk among 80% of women with hormone 
receptor positive breast cancer (187). In a large retrospective analysis, women diagnosed with 
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early breast cancer had increased 10-year incidence of ischemic heart disease, arrhythmias 
and cerebrovascular disease rather than heart failure, compared to controls (188). Despite 
younger age and presence of fewer risk factors among those diagnosed with breast cancer and 
treated with anthracyclines and/or trastuzumab, the risk for cardiovascular disease was 
increased compared to age-adjusted population (188). 
A unanimous definition of chemotherapy-related cardiotoxicity is difficult, but it is generally 
considered to be related to either direct damaging effect of the cancer therapy on the heart 
function and structures or, among patients with cardiovascular risk factors, the acceleration of 
the development of cardiovascular disease (189). In an effort to structure this complex and 
heterogeneous field, Ewer and Lippman reported a classification system based on injury type, 
reversibility and presence of structural abnormalities (190, 191). They characterised Type I 
chemotherapy-induced cardiotoxicity as cardiomyocyte death, with dose-depended and 
irreversible damage, and Type II as cardiomyocyte dysfunction with largely dose-independent 
and reversible damage (190, 192-195). Anthracyclines have long been considered the 
prototype of type I chemotherapy-induced cardiotoxicity whereas trastuzumab-related 
toxicity is considered primarily of reversible type II toxicity. However, the system was not 
absolute and combined damages were soon described, such as for example scar formation 
among patients with presumably type II cardiotoxicity (196). Therefore, Perez et al 
recommended the addition of three more categories; type III coronary disease related (e.g. 
due to radiotherapy or 5-FU), type IV miscellaneous including myocarditis or Takotsubo’s 
cardiomyopathy and type V indirect cardiotoxicity that is related to conduction abnormalities, 
arrhythmia and hypertension (197). 
In a harmonisation effort, the European Society of Cardiology (ESC) proposed a diagnostic 
algorithm for cardiotoxicity, depending on the modality used and divided cardiovascular 
complications of cancer therapy in nine different categories. The recommended cut-off value 
for echocardiography, suggestive of cardiotoxicity is “reduction of left ventricular ejection 
fraction (LVEF >10%) to a value below the lower normal limit”(189). Other modalities 
recommended for screening of cardiotoxicity include cardiac MRI and biomarkers such as 
Troponin I, high-sensitivity troponin I and the natriuretic peptides B-type natriuretic peptide 
(BNP) and N-terminal fragment B-type natriuretic peptide (NT-proBNP) (189). LVEF is 
defined as the percentage of the total volume of blood in the left ventricle ejected at each 
heart contraction. Heart failure is a syndrome related to the existence of typical symptoms or 
signs; symptoms such as shortness of breath, ankle oedema and fatigue, and signs such as 
peripheral oedema and elevated jugular venous pressure may also accompany it (198). 
According to the ESC guidelines heart failure is currently divided into three categories 
depending on LVEF levels (198). Heart failure with reduced EF (HFrEF) is characterised by 
EF <40% whereas heart failure with preserved EF (HFpEF) is characterised by LVEF >50% 
accompanied by symptoms and/or signs, elevated natriuretic peptides and either structural 
changes in the heart or diastolic dysfunction (198). Similar clinical criteria but LVEF values 
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between 40-49% characterise the third category, namely heart failure with mid-range EF 
(HFmrEF) (198). 
Risk factors and onset of cancer therapy-related cardiotoxicity of adjuvant breast cancer therapy drugs  
Anthracyclines Cyclophosphamide Taxanes Anti-HER2 therapy 
Risk factors 
Infusion time 
(bolus administration 
increases risk for 
cardiotoxicity) 
Total bolus dose 
(seen mostly in doses 
>140 mg/kg) 
Cardiotoxicity risk unclear 
due to lack of data and 
interaction with other 
agents such as 
anthracyclines. 
Short time between 
anthracyclines and anti-
HER2 treatment 
 
Lifetime cumulative 
dose 
 
 Arrhythmias related to 
taxanes have been 
described; bradycardia, 
atrioventricular block, 
conduction disturbances, 
atrial fibrillation, 
subraventricular and 
ventricular tachycardias. 
 
Other concomitant 
chemotherapy, 
immunotherapy or 
targeted therapies 
Other concomitant 
chemotherapy 
 
Concomitant or previous 
use of anthracyclines 
 
Mediastinal irradiation Mediastinal irradiation  Mediastinal irradiation 
Pre-existing heart 
conditions 
Hypertension 
  Pre-existing heart condition/ 
low LVEF 
Hypertension 
Age 
(>65 years old or 
paediatric population) 
Older age  Older age 
Renal failure 
Female gender 
 
  
 
 High BMI 
 
Onset 
Acute (<1%) 
Early (within 1 year) 
Late (several years, 
median 7 years) 
Acute  During treatment 
 
Table 2. Risk factors and onset of cancer therapy-related cardiotoxicity of commonly used adjuvant breast 
cancer therapy drugs; anthracyclines, cyclophosphamide, taxanes and anti-HER2 treatment. BMI: Body Mass 
Index, HER2: Human epidermal growth factor receptor-2, LVEF: Left ventricular ejection fraction.  
 26 
The recommended by ESC categories of cardiovascular complications are (189): 
1. Myocardial dysfunction and heart failure 
2. Coronary artery disease 
3. Valvular disease 
4. Arrhythmias, especially those induced by QT-prolonging drugs  
5. Arterial hypertension  
6. Thromboembolic disease 
7. Peripheral vascular disease and stroke 
8. Pulmonary hypertension and 
9. Pericardial complications.  
 
Several efforts are made also by other organisations to provide a common definition of cancer 
therapy-related cardiotoxicity. For example, the Food and Drug Administration (FDA) 
defines it “as >20% decrease in LVEF when baseline LVEF is normal, or >10% decrease 
when baseline LVEF is not normal” (199). On the other hand, the recently published ESMO 
consensus guidelines consider LVEF decline by 10%, and especially if below the absolute 
value of 50%, qualifying as cardiotoxicity requiring further assessment and management 
(200). Despite reduction of LVEF by 10 points being the historically available cut-off value, 
recent studies, such as the SHORT-Her study adapted LVEF decline from baseline by 15 
points as cardiotoxicity indicator (115, 200). 
Observed indications of chronic myocardial damage expressed as elevated troponin measured 
at one of the follow-up visits in the Atherosclerosis risk in communities project (ARIC), in 
cancer survivors even after adjustment for “traditional” cardiovascular risk factors, imply 
distinct pathophysiology among cancer survivors than population (201). These findings 
support publications challenging the theory of distinction between acute and late-onset 
cardiotoxicity, meaning there is probably one process that is identified at different stages. 
Cardinale et al, reported development of asymptomatic anthracycline-induced 
cardiomyopathy among patients with normal baseline LVEF and no severe comorbidity, after 
mean follow-up of 5 years in about 9% of the patients; 98% of which had occurred within 
one year but were subclinical (202). An earlier publication by the same group reported that 
shorter time to treatment start of cardiac medication was related to good recovery after early 
diagnosis and immediate initiation of indicated cardiac medication for patients with LVEF 
45% or less (203).  
Another highly debated aspect is the stand on cardioprotection and up to date there is no 
conclusive data. The OVERCOME randomized study (n=90) reported improved outcomes 
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with prophylactic enalapril and carvedilol in intensively treated patients with haematological 
malignancies (incidence of death, heart failure or final LVEF<45%; 6.7% vs. 24.4% in 
control arm, p = 0.02) but the MANTICORE 101-Breast (n=99) did not show benefit of 
primary cardioprotection during adjuvant therapy for early breast cancer (204, 205).  
Cardiotoxicity related to adjuvant therapy after breast cancer is an important issue, not only 
for a healthy survivor, but also in the case of relapse and/or metastatic disease and primarily, 
but not exclusively, for patients with HER2 amplified breast cancer. Taking into account the 
increased risk of cardiovascular disease in older age, it is highly probable that patients with 
primary or metastatic breast cancer present with cardiovascular disease, a risk factor for 
cardiotoxicity per se. At the same time, when diagnosed with cancer, a life-threating disease, 
the patients should not be deprived of curating treatment due to the fear of cardiac 
complications. Thus, optimal monitoring, management and potential benefit from early 
interventions or even cardioprotection in selected patients in high risk for cardiotoxicity 
remains an unmet need. 
 
Anthracycline-associated cardiotoxicity 
Anthracyclines were extracted from the Streptomyces bacterium and doxorubicin and 
epirubicin are two members of the anthracycline family administered in early and metastatic 
breast cancer. These two drugs are an integral part of adjuvant breast cancer regimens such as 
5-fluorouracil, doxorubicin and cyclophosphamide (FAC), 5-fluorouracil, epirubicin and 
cyclophosphamide (FEC), doxorubicin and cyclophosphamide (AC) and docetaxel, 
doxorubicin and cyclophosphamide (TAC). Their harmful effect to the cardiomyocytes, in 
form of cardiotoxicity, is related primarily to cumulative dose, age, pre-existing heart 
conditions and way of administration (injection) (192, 206-208). Administration of 
doxorubicin over 48 or 90 hours prevented cardiotoxicity in contrast to a short infusion of 15-
30 minutes (209). 
A retrospective, registry-based follow-up of a randomised study (n=961) with a median 
follow-up of almost 17 years, demonstrated a 3-fold increase in cumulative risk for heart 
failure for patients treated with epirubicin (23/446) based polychemotherapy compared to 
CMF (9/515), even at mean epirubicin dose about 450 mg/m2 (210). On the other hand, the 
large meta-analysis by EBCTCG in 2011 supports breast cancer survival benefit transcends 
over cardiotoxicity and subsequent cardiac mortality from anthracyclines (84). Thus, 
appropriate assessment of the cardiotoxicity risk versus breast-cancer survival benefit is of 
major value for the individual patient and risks versus benefit should be properly 
communicated to the patient. 
Redox recycling through generation of reactive oxygen species (ROS) was initially believed 
to be the major mediator of anthracycline-related cardiotoxicity (211, 212). In recent years, 
alternative pathways have been proposed, such as myofibrillar disarray, mitochondrial 
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apoptosis and disruption of sarcomeres (211, 213-215). The different pathways involved in 
anthracycline-related cardiotoxicity are described in figure 7 (216). Anthracyclines are 
considered to cause cytotoxic effects through inhibition of topoisomerase II and differential 
action on tumour cells and cardiomyocytes has been proposed (211, 216, 217). 
Topoisomerase II is an enzyme involved in regulating DNA tangles by cutting both the DNA 
strands of a DNA helix simultaneously and after the repair is complete, the pairs are brought 
together again. Inhibition of topoisomerase II does not allow for the repair of the DNA 
leading to cell death. Topoisomerase II is classified in two categories, IIa and IIβ, and current 
data support that anthracycline anti-cancer effect is mediated by inhibition of topoisomerase 
IIα whereas detrimental effects on cardiomyocytes are caused through inhibition of 
topoisomerase IIβ and lethal DNA double strand breaks (211, 216). 
Morphological changes in the cardiomyocytes have been demonstrated even in doxorubicin 
doses as low as 200 mg/m2. Nowadays, doxorubicin is administered up to a maximum 
cumulative dose of 400-450 mg/m2 since the risk for cardiotoxicity increases exponentially in 
higher doses (218). Other derivatives such as epirubicin and pegylated doxorubicin are less 
cardiotoxic at equivalent myelosuppressing doses, thus allowing for higher cumulative doses. 
A ratio of 0.5:1 epirubicin-to-doxorubicin has been identified for equivalent cardiotoxic 
potential and 0.75:1 for equivalent myelotoxicity (219). 
Even though initially no maximum cumulative dose was established for epirubicin, Nielsen et 
al reported in 1990 severe cardiotoxicity from epirubicin cumulative doses exceeding 1000 
mg/m2 (220, 221). Later on, it was shown that cumulative risk of cardiotoxicity increased 
exponentially up to 15% at 1 000 mg/m2 in contrast to 4% and 1.4% for doses 900 mg/m2 and 
<600 mg/m2 respectively (221-223). As a result, maximum epirubicin cumulative dose is 
currently at 900 mg/m2 (189). However, a study of Danish population with metastatic breast 
cancer revealed that a 5% risk for cardiotoxicity translated to varying maximum tolerable 
cumulative epirubicin dose depending on the patient’s age, comorbidity, hormonal therapy 
and chest irradiation (220). Thus, the maximum cumulative dose and risk for cardiotoxicity 
for the individual should be considered in relation to the presence of confounding factors. 
Figure 8 graphically presents reported cumulative cardiotoxicity incidence at different 
cumulative dose levels of doxorubicin and epirubicin from historical and more recent 
publications (189, 206, 221, 223, 224).  
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Figure 7. Pathways involved in anthracycline-associated cardiotoxicity. ROS: Reactive oxygen species  
(Adapted and reprinted from J Am Coll Card, Vejngposa and Yeh, 2014:64:938-945, ©2014 with permission 
from Elsevier)  
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Figure 8. A compilation of reported cumulative incidence of doxorubicin and epirubicin-associated 
cardiotoxicity. 
 
Trastuzumab-associated cardiotoxicity 
HER2 is expressed in the cardiomyocytes and in the presence of neuregulin has an important 
role in to myocardial stress adaptation and survival (225). The effect of HER2 is mediated by 
regulation of apoptosis, cell growth, cell adhesion and angiogenesis, through activation of 
signalling pathways like extracellular signal-regulated kinase (ERK), 1/2-mitogen activated 
protein kinase (MAPK) and phosphoinositide-3-kinase-Akt (PI3K-Akt) (figure 9) (226). In 
animal studies, cardiac –restricted HER2 knockout mice exhibit abnormal cardiac 
development and dilating cardiomyopathy features (227). In contrast to anthracyclines, the 
structural and functional changes on the cardiomyocytes and inhibition of contractile 
elements caused by trastuzumab do not lead to cell death and therefore this kind of toxicity is 
considered reversible (189, 190, 228). Compromised cell recovery and repair by trastuzumab 
after anthracycline-related cell damage is considered to underlie increased incidence of 
cardiotoxicity when trastuzumab and anthracyclines are given concomitantly or in sequence 
but within very short interval (226).  
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Figure 9. HER2 signalling pathway in the cardiomyocyte and in cancer cells. ERBB2, also known as HER2-
neu: Epidermal growth factor 2, ERBB4, also known as HER4: Epidermal growth factor 4, FAK: Focal 
adhesion kinase, JAK-STAT: Janus kinases- signal transducer and activator of transcription proteins, MAPK: 
mitogen-activated protein kinase, NRG1: Neuregulin 1, PI3-AKT: phosphatidylinositol 3-kinase–AKT 
(Reproduced with permission from Cote el al, N Engl J Med 2012;367:2150-2153, © Massachusetts Medical 
Society) 
 
The true incidence of trastuzumab-induced cardiotoxicity, the ideal window between 
anthracyclines and trastuzumab administration and the status of prophylactic cardiac 
medication are still disputed. The initial studies performed by Slamon, investigating efficacy 
of trastuzumab in patients with metastatic HER2 positive breast cancer, surprisingly revealed 
27% heart failure of New York Heart Association functional class (NYHA) III or IV among 
patients treated with concomitant anthracyclines and trastuzumab compared to 8% of those 
not receiving addition of trastuzumab (100, 229).  An independent Cardiac Review and 
Evaluation Committee (CREC) was founded with mission to supervise trastuzumab trials. 
The CREC established some criteria and described trastuzumab-cardiotoxicity syndrome “as 
decline in left ventricle ejection fraction (LVEF) of at least 5% to less than 55% with 
accompanying signs or symptoms of congestive heart failure (CHF), or a decline in LVEF of 
at least 10% to below 55% without accompanying signs or symptoms” (229). Reflecting the 
impact of previous delivered chemotherapy, an assessment of the early trastuzumab trials by 
the CREC reported cardiac dysfunction, according to published predefined criteria, up to 3% 
when single trastuzumab was administered as first line treatment and 5% when administered 
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as second or third line (229). Subsequent adjuvant trials have reported markedly lower 
cardiotoxicity incidence; as high as 7.3% (107, 230). Notably, younger, healthy individuals 
with normal LVEF and no pre-existing cardiac conditions were enrolled in these trials, not 
always reflecting the population treated in real life conditions.  
The HERA trial reported asymptomatic or mildly symptomatic heart failure with significant 
LVEF drop by 10% below baseline and below 50% among 4.4% of patients treated with 
trastuzumab for 1 year but almost the double after two years trastuzumab (7.3%) (107). Even 
if trastuzumab-induced cardiotoxicity is considered to be dose-independent most studies 
investigating shorter trastuzumab duration report increased cardiotoxicity with longer 
treatment duration (114, 115, 118, 231). A recently published meta-analysis of six trials 
reported compared 1-year trastuzumab with shorter duration. One-year trastuzumab increased 
pooled risk for cardiac dysfunction (defined as heart failure or significant LVEF decline) 
compared to shorter treatment intervals (8.2% vs. 4.8%) but the overall incidence remained 
low and less than 10% (232). 
The prospective observational OHERA study included non-selected patients (n=3 938) that 
fulfilled the indication for adjuvant trastuzumab (233). Cardiac assessments were performed 
per local guidelines and therefore introduce heterogeneity in the results. Interestingly 49 
patients (1.3%) had known history of heart failure at baseline and approximately 42% had 
more than one known risk factor for cardiovascular disease. Only a small percentage of the 
patients developed heart failure (n=160, 2.8%) and median time to diagnosis was 5.7 months 
(233). Unsurprisingly, five of six patients suffering cardiovascular death had pre-existing 
cardiovascular risk factors (233). The study confirmed previously reported risk factors for 
trastuzumab-related cardiotoxicity such as pre-existing cardiac conditions, hypertension, 
obesity and age over 65 years and, additionally, identified normal range but low baseline 
LVEF (≤55%) as independent risk factor (233). Table 3 presents incidence and definition of 
cardiac events reported in some of the adjuvant trastuzumab trials with varying trastuzumab 
duration (107, 114, 115, 230, 233-235). Difference in the definition of cardiac events, 
assessment and duration of follow-up should be taken in consideration.  
Early phase studies of (neo)adj T-DM1 with treatment duration 1 year demonstrate reportedly 
low incidence of asymptomatic LVEF decline (2.7%, n=4) but no cardiovascular events or 
heart failure (236). A recent individual patient data pooled meta-analysis of T-DM1 trials 
including 1961 patients showed low rates of cardiotoxicity with heart failure/significant 
LVEF drop as low as 0.71% and cardiac ischemia 0.1% and a total rate for cardiotoxicity at 
3.37% (237). Age over 65 years, low baseline LVEF (below 55%) and the combination of T-
DM1 with pertuzumab were identified as risk factors for T-DM1 related cardiotoxicity (237).  
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CARDIAC SAFETY ENDPOINTS IN SELECTED ADJUVANT TRASTUZUMAB TRIALS 
Study Number of 
patients 
Trastuzumab duration Primary cardiac safety 
endpoints 
Outcome 
SHORT-HER 
(Conte el al, 2018) 
N=1254 1 year 
vs. 
9 weeks 
- LVEF decline >15% or LVEF 
decline >10% & absolute value 
<50% 
- Heart failure 
- Other cardiac events of grade ≥2 
 
9 weeks 4.3% 
1 year 13.1% c 
 
SOLD 
(Joensuu et al, 2018) 
N=2174 1 year 
vs. 
9 weeks 
 
Heart failure, myocardial 
infarction or cardiac/coronary 
surgery 
9 weeks 2%c 
1 year 4% 
PERSEPHONE 
(Earl et al, 2019) 
N=4089  
1 year 
vs. 
6 months 
 
- Symptoms of cardiac disease 
and/or signs of HF and/or 
new/altered cardiac medication 
within 12 months from 
trastuzumab start  
 
-LVEF absolute value <50% or 
reported as low without 
quantification 
 
6 months 8%c 
1 year 11% 
 
 
 
 
6 months 9% 
1 year 11% 
HERAa 
(Cameron et al, 2017) 
N=5102 2 years 
vs. 
1 year 
 
- NYHA III-IV 
- LVEF decline >10% & absolute 
value <50% 
- Cardiac death 
 
1 year 1% 
2 years 1% 
BCIRG06a 
(Slamon et al, 2011) 
N=3222 1 year trastuzumab and: 
anthracycline 
chemotherapy  
(AC-TH) 
vs. 
non-anthracycline 
chemotherapy (TCH) 
 
- Heart failure  
 
 
- Sustained asymptomatic  
LVEF decline >10% 
AC-TH 2%c 
TCH 0.4% 
 
AC-TH 18.6%c 
TCH 9.4% 
OHERAb 
(Lidbrink et al, 2019) 
N=3938 Included patients fulfilling 
recommendation for 1 year 
trastuzumab 
 
- Symptomatic HF (NYHA II-IV) 2.8% 
 
(NYHA III-IV 1%) 
Table 3. Reported incidence of cardiac adverse events in selected adjuvant trastuzumab trials with varying trastuzumab 
treatment duration. AC-TH: Doxorubicin/Cyclophosphamide (AC) followed by docetaxel/trastuzumab (TH) with 
trastuzumab duration for 1 year, HF: heart failure, LVEF: Left ventricular ejection fraction, NYHA: New York Heart 
Association functional class, TCH: Docetaxel/carboplatin/trastuzumab with trastuzumab duration one year 
aThe group that was treated with trastuzumab is not reported here, bNon-randomised observational study, cp ≤0.01.  
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Other anti-HER2 agents have also shown low cardiotoxicity rates and combinations have not 
increased cardiotoxicity rates. Dual HER2 blockage with the addition of pertuzumab to 
trastuzumab did not exacerbate cardiac safety (110, 119, 238-241). In fact, in the 
CLEOPATRA trial, there were numerically less left ventricle dysfunction events in the 
combination of docetaxel, trastuzumab and pertuzumab (6.6%) than in the docetaxel and 
trastuzumab group (8.6%) (119). It is unclear whether this is a chance finding or if there 
could a plausible biological explanation related to the distinct way the two drugs block HER2 
activation. Likewise, a pooled analysis of the combination of pertuzumab with non-
anthracycline chemotherapy, trastuzumab or erlotinib revealed no added cardiotoxicity (242). 
Moreover, lapatinib and trastuzumab alone, in combination or in sequence, reported 
cardiotoxicity between 2-3% (109, 243). A meta-analysis of different lapatinib studies also 
reported cardiac adverse events as low as 3% (244). Finally, neratinib in sequence or in 
combination with trastuzumab does not either demonstrate significant cardiotoxicity (245-
247). 
In the majority of the patients that develop trastuzumab-related heart failure, LVEF recovers 
on average 6-9 months after treatment discontinuation (233, 248). Patients with 6 months 
trastuzumab recovered more rapidly than the ones that received 12 months treatment in the 
PERSEPHONE trial (112). Nonetheless, continuing trastuzumab even after LVEF decline 
below 50% seems to be relatively tolerable (249). In a retrospective analysis including 60 
patients by Houssain et al, the majority of the patients (61%) that continued trastuzumab 
besides reduced LVEF could continue without cardiac event and only 13 % developed a 
cardiac event (249). As expected, almost all patients (91%) received cardiological care with 
introduction or titration of cardiac medication and after median follow-up of 633 days there 
was no difference in the final LVEF between patients that interrupted trastuzumab (and 
eventually restarted afterwards) and the ones that continued with trastuzumab (54% vs. 
56%, p=0.29) (249).  
In similar manner, initiation of anti-HER2 treatment in patients with baseline LVEF less than 
50%, even if asymptomatic, has been met with reservation. The results from the SAFE-
HEaRT study though reported that up to 90% (27 out of 30) of asymptomatic patients with 
LVEF 40-49% at baseline could complete planned anti-HER2 treatment with proper cardiac 
medication and cardiac monitoring (250).  
In summary, anti-HER2 agents are integral part of HER2 positive breast cancer management 
with undisputable impact on survival. Interpretation of the results from various publications 
calls for caution since different definitions of cardiotoxicity are used and varying 
chemotherapy regiments in combination or in sequence with trastuzumab have been 
administered in different studies. 
Cyclophosphamide and cardiotoxicity 
Cyclophosphamide is an alkylating agent belonging to the nitrogen mustard family and is 
administered in combination with anthracyclines during treatment for early or metastatic 
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breast cancer. Sulphur mustard was a milestone in the development of chemotherapy and it 
was the first chemotherapeutic to be tested in a clinical trial. 
Cardiotoxicity with acute onset related to cyclophosphamide has been described and it is 
related to high delivered dose at one occasion (> 150mg/kg) rather than cumulative dose 
(251, 252). In doses over 150 mg/kg acute heart failure up to 33% is reported with onset 
within days or few weeks and dose per administration (calculated on weight or body surface 
area) is directly related to the risk of cardiotoxicity (252, 253). It is suggested that the 
cyclophosphamide metabolites 4-hydroxy-cyclophosphamide and acrolein, mediate 
cardiotoxicity through ROS generation and suppression of the activity of aldehyde 
dehydrogenase leading to complex pathways (254). Partly, the mitochondria are damaged by 
ROS and impediment of the Krebs cycle by increased mitochondrial membrane permeability 
(255). Furthermore, ROS generation and subsequent oxidative stress can activate nuclear 
factor kB (NF-kB) leading to cytokine release (256).  
When administered in immunomodulating aim such as in rheumatological conditions or to 
prevent graft rejection, cyclophosphamide doses are low and the risk for cardiac adverse 
events is expected to be insignificant. In breast cancer, cyclophosphamide is usually given in 
combination with anthracyclines in doses 500-600 mg/m2. A person with a mean body 
surface area of 1.73 m2 would then be expected to receive 865 – 1038 mg; doses below those 
expected to increase the risk for cardiotoxicity. However, in protocols such as the PANTHER 
trial that will be discussed in the current thesis, cyclophosphamide doses can escalate up to 
1200 mg/m2. Even though, the risk for cyclophosphamide-related acute cardiotoxicity is not 
entirely negligible, one would not expect cyclophosphamide to impose major impact on the 
risk and incidence of long-term cardiotoxicity.  
Taxanes and cardiotoxicity 
These microtubuli inhibitors belong to a drug class called plant alkaloids and as the name 
implies they are derived from plants; specifically from the Pacific Yew tree. Docetaxel and 
Paclitaxel are the ones commonly used in the management of breast cancer. In early breast 
cancer, taxanes are most often used in sequence to anthracycline regimens, although taxane-
only schedules in combination with trastuzumab are now also an option for HER2 positive 
early breast cancer. Taxanes are considered to disturb the conduction system of the heart and 
potentially cause arrhythmias. They have not shown the same cardiotoxic potential as 
anthracyclines and are regarded as a safe alternative, even though the cumulative risk is 
unclear. Data from trials investigating anthracycline-free regimens demonstrate low rates and 
indifferent cardiotoxicity incidence between anthracycline/cyclophosphamide and 
docetaxel/cyclophosphamide combinations but long-term data are scarce (257-259).  
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Fluorouracil and cardiotoxicity 
Fluorouracil (5-FU) and its oral pro-drug capecitabine are synthetic drugs and are widely 
used across different solid tumours as single therapy, in chemotherapeutic combinations and 
as radiosensitisers during radiotherapy.  
Cardiotoxic potential is mediated mainly due to endothelial injury and vasospasm-induced 
ischemia during the treatment period and presented as angina, myocardial infarction and 
ventricular arrhythmia (260). However, not all symptomatic patients have findings in line 
with vasospasm or endothelial damage and transient changes similar to Takutsubo’s 
cardiomyopathy has also been suggested as underlying mechanism (261). Reported data 
provide varying but low incidence (<10%) of fluorouracil-related ischemia but, once 
manifested, can be fatal to 8% of the patients (262). Efforts to re-challenge should be 
accompanied with caution due to 90% risk for recurrence of symptoms and mortality up to 
13% (261).  
Administration as infusion causes toxicity in 2-18% and pharmacodynamics during 
administration as oral capecitabine are comparable to bolus or short infusion (261). The risk 
for cardiotoxicity (3-9%) was similar to infusion administration implying that both treatment 
schedule and drug-specific pharmacokinetics impact the risk for cardiotoxicity in this case 
(261). 
1.10 Neutropenia and G-CSF prophylaxis 
Haematological toxicity in the form of anaemia, leukopenia/neutropenia and 
thrombocytopenia is common dose-limiting toxicity following chemotherapy administration. 
Neutropenia can be complicated with fever (febrile neutropenia, FN) or opportunistic 
infections. FN is a potentially life-threatening condition, can require hospitalization, 
antibiotics administration and impose considerable health economic costs on both the patient 
and the health care system. The common terminology criteria for adverse events (CTC AE) 
version 3.0, describes FN as fever over 38.5 oC and absolute neutrophil count [ANC] <1.0 
x109/L whereas the more recent version 5.0 requires fever over 38.3 oC as single measure or 
at least 38 oC persisting for more than one hour.  
About 8 patients per 1000 receiving contemporary standard-dose chemotherapeutics develop 
FN (263). Median length of hospitalization due to FN for breast cancer patients is reported to 
4 days and mean cost per hospitalization in Western countries is estimated at approximately 
13 500 € (263, 264). Development of neutropenia and FN can have an impact on dose 
intensity during chemotherapy, which in turn can negatively affect cancer related outcomes 
(89, 95, 265). A meta-analysis including 10 trials performed by Kuderer et al, reported 
increase in mean relative dose intensity with granulocyte-colony stimulating factor (G-CSF) 
support from 86.7% to 95.1% (mean difference 8.4%, p=0.001) (266).  
The use of exogenous G-CSF has shortened the length of neutropenia, length of 
hospitalization and severity of febrile neutropenia but potential impact on mortality is debated 
(266, 267). G-CSF is a main regulator of granulopoiesis and the survival, proliferation and 
differentiation of granulocytes (neutrophils, basophils and eosinophils); the body’s critical 
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soldiers against microbial infections and inflammatory processes. Initially it has a synergistic 
action with “early acting cytokines” and promotes the proliferation of hematopoietic stem 
cells, which in turn will engage in myeloid differentiation for the production of neutrophils 
(268, 269). Subsequently, G-CSF acts as “late acting cytokine” and influences granulocyte 
maturation (268). Expression of the G-CSF receptor is encountered in both immature 
myelocytes and mature neutrophils and it seems that G-CSF levels are regulated by the latter 
through a negative-feedback loop (270). Exogenous administration of G-CSF has been shown 
to expand the mitotic pool of progenitor granulocytes (myeloblasts, promyelocytes, 
myelocytes) and mobilise the postmitotic pool (metamyelocytes to neutrophils) (268). 
Finally, G-CSF administration can also promote peripheral neutrophil activation (271). 
Use of G-CSF has also permitted for higher relative dose intensity without excess 
myelotoxicity (272). G-CSF primary prophylaxis is recommended by international guidelines 
for chemotherapy regimens with risk for FN 20% or above (263, 273, 274). Risk assessment 
should include: i) tumour factors such as cancer type and stage, ii) planned chemotherapy 
regimen and iii) patient-related factors such as age, comorbidities, poor performance, low 
baseline blood cell counts, tolerance of previous chemotherapy or previous episode of 
neutropenic fever (263, 274).  
Over time there has been a steady decline in mortality related to neutropenic complications 
from 10% to 5.4% (275). Breast cancer patients have had low FN in-hospital mortality 
compared to FN in other malignancies and it has been accordingly declining (276). FN in-
hospital mortality was reported at 3.6% in 2006 by Kuderer et al but Pathak et al in 2015 
reported incidence of in-hospital mortality related to FN reduced to 2.6% (276, 277). The 
reduction of FN related mortality has been attributed to the use of less toxic chemotherapeutic 
agents, more effective treatment of FN and awareness for early detection of sepsis (275).  
The available G-CSF agents are divided into two major categories: the short-acting filgrastim, 
and the long-acting pegfilgrastim. Filgrastim is cleared by the kidneys and requires 
administration several days in a row until the nadir phase is passed as depicted in figure 10. 
Pegfilgrastim on the other hand, has a sustained-released formulation that requires only one 
administration after each chemotherapy cycle and is cleared through circulating neutrophils. 
Despite the well-documented beneficial effect of G-CSF, adherence to guidelines has not 
been optimal. Occasionally, patients do not receive G-CSF prophylaxis in spite of adequate 
risk level, or G-CSF prophylaxis is discontinued early during the chemotherapy course 
without coverage for all cycles (278). Based on observations that the risk for FN is highest 
during the first two cycles but then declines, a phase III study, reported by Aarts et al, 
compared administration of G-CSF for only the first two cycles of adjuvant breast cancer 
chemotherapy or all subsequent cycles (279). The study had to close prematurely after an 
interim analysis revealed 5 times higher risk of FN (HR 5.4, 95% CI 2.3 – 12.6) when G-CSF 
administration was limited to the first two cycles (38%) compared to prophylaxis at every 
chemotherapy cycle (10%) (279). These results, together with the fact that 24% of the 
patients who discontinued G-CSF after two cycles developed FN after the third cycle, further 
underline the importance and benefit of G-CSF prophylaxis.  
FEC followed by docetaxel (D) is widely used for adjuvant or neoadjuvant treatment of 
breast cancer. This schedule was in the PACS01 trial compared to six cycles of FEC and  
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Figure 10. Elimination of filgrastim and pegfilgrastim. G-CSFR: Granulocyte colony stimulating factor 
receptor. (Reprinted from Crit Rev Onco Hematol, 72(1):21-44, Crea et al, © 2009, with permission from 
Elsevier). 
 
grade 3-4 FN was reported among 11.2% of the patients treated with the FEC/D sequential 
schedule, compared to 8.4% of patients receiving only FEC (280). It is worth mentioning that 
only secondary G-CSF prophylaxis was allowed in the protocol and if G-CSF was 
administered during FEC, it was discontinued upon docetaxel initiation (280). A retrospective 
study by Miguel et al, reported even higher FN incidence of 21% during docetaxel and 7% 
during EC (281).  Additional retrospective data report 26% FN among 168 patients that were 
treated with FEC-D and about half of the events occurred during FEC and half during D 
(282). The same study reported also three-fold higher incidence of FN among patients that 
did not receive G-CSF versus those who did; 31% versus 10%. Interestingly, patients that 
received trastuzumab in combination with chemotherapy reportedly had higher risk for 
developing FN. Febrile neutropenia grade 4 despite pegfilgrastim prophylaxis was reported in 
14% of patients that received anthracycline and cyclophosphamide after previous taxane and 
carboplatin in a recent neoadjuvant Belgian study (283). 
Whether any of the two G-CSF formulations is superior than the other is debated. A recent 
meta-analysis showed little difference between the two, and supports that potential 
superiority of pegfilgrastim could be related to suboptimal dosing of short-acting filgrastim 
(284). Conversely, early reports from 2009 and 2013 claim higher cost effectiveness with 
pegfilgrastim and also underline the patient-perspective of only receiving one injection (285, 
286).  
The initial approval of filgrastim in 1991 recommended initiation of treatment already 24 
hours after chemotherapy completion until absolute neutrophil count (ANC) was over 10 x 
109/L and duration could be up to two weeks. Mean reported duration in early clinical trials 
was 10-11 days (287). However, in real life setting and subsequent clinical trials, delayed 
start and shorter treatment duration demonstrated equivalent effect and shorter duration is 
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most usually used today (288-290). Nowadays, ESMO guidelines recommend administration 
of filgrastim at 5 µg/kg/day s.c. within 24-72 hours after chemotherapy and until the ANC 
nadir is over, usually at ANC levels of 2-3 x 109/L (263). Pegfilgrastim is recommended at a 
single fixed dose of 6 mg the day after chemotherapy (263). There is data implying 
administration of pegfilgrastim 72 hours after chemotherapy could be more beneficial by 
causing less leucocytosis while maintaining adequate prophylaxis towards neutropenia (291). 
However, it is early data from a small non-randomised study and should be assessed 
accordingly.  
The most commonly reported side effect during administration of G-CSF is bone and/or 
musculoskeletal pain and it was reported up to almost 20% of patients in a review including 
17 randomised trials (266). Pathogenesis of G-CSF related bone pain is not restrictively due 
to bone marrow quantitative and qualitative expansion; quantitative due to expansion of the 
granulocyte progenitors and qualitative due to stimulation of mature cells and secretion of 
cytokines (292). Other suggested mechanisms are through G-CSF action on pathways 
involved in pain modulation but also through involvement in sensitisation of peripheral 
receptors to nociceptive stimuli by modulating inflammatory response (290, 293, 294).  
Administration of primary G-CSF prophylaxis during adjuvant breast cancer treatment is 
feasible and commonly used. On the contrary, the benefit of adjunctive G-CSF after 
manifested FN is ambiguous. G-CSF administration in combination with antibiotics appears 
to shorten the length of hospitalisation but impact on FN-related mortality is not clear (267). 
Thus, blind administration of G-CSF after manifested neutropenia is not recommended. It 
should, however, be considered in patients with high risk for infection-related complications 
or co-morbidities that predispose to poor outcome in case of prolonged infection and/or 
hospitalization.  
 
1.11 Chemotherapy-induced gonadal toxicity 
Globally, 31% (n=644 753) of women diagnosed with breast cancer in 2018 were younger 
than 50 years old (3). Ovarian ablation by surgery or irradiation or suppression by GnRHa 
improves breast cancer outcomes among women with breast cancer with ER positive or 
unknown status (123). In absolute numbers, 15-year risk for recurrence is improved by 4.3% 
(p<0.001) and risk for breast cancer death by 3.2% (123). Moreover, ovarian suppression 
with luteinising hormone releasing hormone agonists (LHRHa) in addition to tamoxifen, 
chemotherapy, or both, in ER positive breast cancer improved breast cancer recurrence and 
death (126).  
Nevertheless, even in the absence of ablation, ovarian function among young women can be 
impaired due to chemotherapy, leading to amenorrhea and premature menopause 
(chemotherapy-induced amenorrhea, CIA). This becomes more relevant when considering 
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that average age at spontaneous, natural menopause is 51 years (295). The incidence of CIA 
varies greatly from 10% to 97% (296-298).  
Even though loss of primordial follicles is often cited as the cause of CIA, several pathways 
are reported to be involved. Oocyte death through chemotherapy-induced damage to somatic 
cells (necessary for the survival of the oocytes) and “burn out of follicle reserve” in an effort 
to replace apoptosis of developing follicles are alternative pathways (299). Moreover, acute 
vascular damage, reduction of the blood flow in the ovary and fibrosis of the cortical stroma 
have been reported following doxorubicin administration (295). 
The heterogeneity of the reported incidence results depends on a plethora of reasons such as 
type of chemotherapy agents administered and duration of treatment, duration of follow-up, 
age at breast cancer diagnosis and subsequent long-term endocrine therapy. The risk of CIA 
seems to be increased when chemotherapy is administered during the follicular phase of the 
menstrual cycle (300). Mean time to induction of CIA is reportedly shorter in older women 
(2-4 vs. 6-16 months) (301). Addition of tamoxifen leads to a two-fold increase of 
amenorrhea incidence after chemotherapy with or without trastuzumab (OR, 2.12; 95% CI, 
1.13 - 4.00); probably through hypothalamus-ovarian feedback loop (297, 302-305). 
A meta-analysis by Zavos et al, reported increasing CIA incidence with increasing age at 
diagnosis; 26% for women under 35 years old and 77% for women above 40 years old (297). 
A recent combined analysis of the PACS04 and PACS05 studies demonstrated menstruation 
recovery in 63% of women younger than 35 years, 56% amid those aged 35-39 years and a 
drastic reduction to 20% among women older than 40 years (306). Increased risk for 
premature ovarian failure among older women is likely a result of chemotherapy-induced 
destruction of follicles among women with a de facto low primordial follicles reserve (307). 
Even breast cancer survivors who remained, per definition, premenopausal after adjuvant 
chemotherapy have diminished follicle pool and reduced levels of anti-Müllerian hormone 
(AMH) compared to age- and pregnancy-matched controls (302). Administration of 
tamoxifen was related to lower follicle count, AMH and inhibin B and higher estradiol levels 
(302).  
Notably, amenorrhea in direct conjunction to the completion of adjuvant chemotherapy is not 
a sign of permanent premature ovarian failure. Recovery of ovarian function and resumption 
of menstruation has been seen within 24 months after end of chemotherapy. As expected, 
younger women (<35 years) are more likely to resume menstruation than older women and 
up to 85% of the former can recommence menstruation (308). Most available data are due to 
older chemotherapy trials and, nowadays, prolonged duration of endocrine therapy is 
recommended for high-risk breast cancer. Hence, potential impact and confounding of 
adjuvant endocrine therapy and concomitant use of GnRHa should be considered when 
interpreting results and advising a patient. Relation of menstruation recovery and time from 
completion of chemotherapy is depicted in figure 11 (306). 
Infertility is the most commonly associated detrimental effect related to CIA, although not the 
only one. Fertility preservation methods such as oocyte or embryo cryopreservation have 
been developed with success and the field is further developing; for example, with 
  41 
transplantation of ovarian tissue or uterus. Recent reports support GnRHa administration 
during chemotherapy reduces the risk of CIA and premature ovarian insufficiency (309). An 
individual patient data meta-analysis of five major trials by Lambertini et al reported lower 
premature menopause incidence (14.1% versus 39.9%; adjusted OR 0.38, 95% CI, 0.26 – 
0.57) and increased rate of pregnancies (10.3% versus 5.5%) after chemotherapy in 
combination with GnRHa versus chemotherapy alone, without impact on disease-free or 
overall survival (310). A multivariate analysis revealed administration of GnRHa and young 
age at diagnosis as having a prophylactic effect, further supported by the fact that all 
pregnancies presented among women younger than 40 years old at the time of diagnosis 
(310). Thus, GnRHa probably have a place in the prevention of ovarian function and fertility 
without compromising breast cancer outcomes.  
Apart from infertility, ovarian insufficiency in young age can also trigger other long-term 
effects related to low oestrogen levels and can deteriorate quality of life. Such examples are 
menopause-related vasomotor symptoms, osteoporosis and increased risk for cardiovascular 
disease and related mortality due to premature menopause (172, 311). Iatrogenic ovarian 
failure secondary to chemotherapy was found to be related to decreased sexual interest but 
did not independently affect sexual function among women treated for breast cancer (312). 
Hormonal substitution in this population is categorically contraindicated and thus other 
methods should be employed for relief of these patients. 
 
 
Figure 11. Resumption of menstruation up to 24 months after completion of chemotherapy for early breast 
cancer. (Reprinted from Clin Breast Cancer, 19(1):63-70, Pistilli et al, ©2019, with permission from Elsevier) 
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In spite of the notable side effects, the significant survival benefit of this specific 
chemotherapy-related toxicity should be emphasised, not least considering the persistence of 
the CIA-associated improvement of breast cancer outcomes regardless oestrogen receptor 
status (296). In a prospective randomised trial investigating doxorubicin-cyclophosphamide 
(AC) and docetaxel (D) in sequence (AC-T), concomitantly (TAC) or only AC, women with 
premenopausal status at diagnosis and subsequent development of CIA reported improved 
overall survival and disease free survival; RR0.76 and 0.70 respectively (p=0.04 and 
p<0.001) (296). The favourable effect of CIA in terms of disease-free and overall survival is 
further supported by a meta-analysis from 2014 (RR OS 0.60 and RR DFS 0.67) and a 
retrospective analysis of the MA.5 trial (HR OS 0.40, 95% CI 0.22 – 0.72 and HR relapse-
free survival 0.51, 95% CI 0.32 – 0.82) (313, 314).  
Increased chemotherapy-dose intensity is cited to elope greater risk for subsequent CIA. Dose 
intensive chemotherapy in the IBCSG Trial 15-95 resulted in amenorrhea 7-9 months after 
randomisation in 93%, versus 78% after standard chemotherapy (315). Amenorrhea was 
more likely to become permanent after dose intensive therapy and the difference in transient 
and permanent amenorrhea between the two treatment schedules was more prominent among 
women younger than 40 years; 61% versus 24% for the latter (315). Maintaining same 
cumulative dose but increasing dose-density has not led to increased CIA incidence (305, 
316, 317). 
Even if cumbersome, assessment of menopausal status is of paramount importance for 
women with hormone receptor positive breast cancer in order to decide upon appropriate 
endocrine therapy. Even though AIs are superior to tamoxifen, establishing a patient is 
postmenopausal prior to treatment initiation is a prerequisite. Thus, efficacy of AIs in women 
with ovarian function, even if not at adequate levels to cause menstruation, is impeded by 
simultaneous estradiol production in the ovaries. Moreover, AIs in seemingly 
postmenopausal young women can stimulate the hypothalamus/pituitary pathway and 
subsequently increase estradiol levels by FSH release (318). Figure 12 presents hormonal 
regulation of oestrogen production through the hypothalamus/pituitary-ovaries pathway in 
premenopausal women.  
Despite addition of GnRHa to AI when offered to young premenopausal patients, complete 
ovarian function inhibition needs to be ensured due to potential survival concerns otherwise 
(129). Since ovarian function may spontaneously recover several months after the end of 
chemotherapy, hormone-levels shortly after chemotherapy administration should not be 
considered reliable. Thus, a patient’s age, menopausal status, gynaecological history and 
given chemotherapy should be taken into consideration when assessing probability of 
premature ovarian failure and endocrine therapy.  
Gonadal toxicity and agents used in adjuvant breast cancer chemotherapy regimens 
The type of chemotherapeutic agent used and achieved cumulative dose have a direct impact 
on the risk of CIA (297). Alkylating agents, of which cyclophosphamide is of interest in the 
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Figure 12. Regulation of oestrogen production in the ovaries and follicle development in premenopausal 
women. (Modified from Papakonstantinou A et al: J Clin Oncol 34: 1573-1579, 2016, Reprinted with 
permission. © 2016 American Society of Clinical Oncology. All rights reserved.) 
 
treatment of early and metastatic breast cancer, are considered highly toxic to the ovaries 
damaging both resting and growing follicles (319). Cyclophosphamide is reportedly related to 
permanent CIA in up to 97% of women older than 40 years old (298). The lack of cell-cycle 
specificity is considered to be responsible for the 4-9.3 fold increased risk of amenorrhea 
among patients treated with cyclophosphamide compared to controls (319). On the contrary, 
cell-cycle specific drugs such as 5-fluorouracil do not seem to impact follicle number (303).  
An early trial published in 1986, reported amenorrhea in 80% of premenopausal women 
treated with doxorubicin-containing regimens (320). The data regarding potency of 
anthracycline-regimens versus CMF in terms of CIA is inconsistent pointing at similar CIA 
incidence after anthracyclines and CMF or increased CIA after CMF, probably due to higher 
cyclophosphamide doses (304, 308, 314). A retrospective analysis of the PACS04 and 
PACS05 trials singled out non-alkylating chemotherapy to increase likelihood of 
menstruation resumption (306).  
The gonadal toxicity related to taxanes is largely unknown. Administered most often in 
combination or in sequence with anthracycline and cyclophosphamide containing regimens, it 
is indeed difficult to investigate actual impact from taxanes. Available studies report 
conflicting results, from reduced CIA incidence to equal and further to increased (295, 301, 
308). Animal studies have demonstrated blockage of ovulation without impact on fertility 
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supporting a transient toxicity (321). In addition, in rat experiments apoptosis was mainly 
seen in mature follicles following paclitaxel administration and fertility was affected directly 
after the infusion but recovered at 24 days (322). Accordingly, potential gonadotoxic effect of 
taxanes is probably mild, transient and diluted in the amenorrhea caused by accompanying 
chemotherapeutics. Fluorouracil does not seem to increase risk for amenorrhea and is also no 
longer used as widely as before in the management of early breast cancer (295). 
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AIM OF THE THESIS 
The overall aim of the thesis was to further examine specific chemotherapy-induced 
toxicities, namely cardiotoxicity, neutropenia prevention and chemotherapy-induced 
premature ovarian failure, and the impact of intensifying chemotherapy intervals and 
individual dose tailoring. 
In particular, specific aims of the thesis were:  
1. To investigate how heart failure after breast cancer diagnosis differs from heart failure 
in the general population in terms of clinical features, aetiology and treatment (Paper 
I). 
2. To investigate exposure, efficacy and cardiac safety of trastuzumab in combination 
with tailored and dose-dense chemotherapy compared to combination with standard 
3-weekly regimen in the PANTHER phase III trial (Paper II). 
3. To investigate incidence of neutropenic events with and without G-CSF and the 
impact of G-CSF on neutropenia related treatment delays (Paper III).  
4. To assess whether tailored and dose-dense chemotherapy can impact CIA incidence 
and breast cancer specific outcomes and whether menopause status at breast cancer 
diagnosis can influence the effect of the allocated chemotherapy regimen (Paper IV). 
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PATIENTS AND METHODS 
3.1  Data source  
 
Registries 
The Swedish National Registries were utilised for Paper I. In Sweden, the existence of a 
unique twelve-digit personal number issued at birth or when migrating to Sweden, enables 
follow-up of patients through life and cross-reference between different national registries. 
All registries but the Swedish Heart Failure Registry are maintained and managed by the 
National Board of Health and Welfare (323). Extraction of data from the registries was 
performed after approval from relevant regional ethics committee in Linköping and 
procedures complied with Swedish legislation valid at the time. 
The Swedish National Hospital Discharge Register (NHDR) was established in 1964 and has 
had complete national coverage since 1987 (324). It contains health care related information 
from in-patient (in-hospital) care and outpatient specialist care but no information from 
primary health care visits is registered. Since 2015, reporting is mandatory on monthly basis. 
The positive predictive value (PPV) of the registry varies between diagnoses but validity is 
generally high and between 85 and 95% (324).   
The Swedish Cancer Registry was founded in 1958 and has national coverage. Reporting of 
all new diagnosed cancer is mandatory by law and the registry is the source of official cancer 
statistics for Sweden. With about 99% of the diagnoses morphologically verified, the registry 
is considered of good quality and a completeness survey by Barlow et al published in 2009 
reported good validity of the registry (325). Underreporting was less than 4% and related to 
site. For example, breast cancer had very low underreporting and probably insignificant 
impact on epidemiological studies (325).  
The Swedish Cause of Death Register (COD), also with complete national coverage, is 
updated annually and includes information from 1961 when computers were introduced and a 
historic registry between 1952-1961. It includes information on deaths of all persons 
registered in Sweden at the time of death; regardless if the place of death is Sweden or 
abroad. However, registration of cause of death for persons not registered in Sweden is 
available only from 2012 and onward. The registry does not include stillborns (326). 
The Swedish Prescribed Drugs Register (PD) has been around in years but it was expanded 
to include the patient’s identification in the middle of 2005 (327). The registry uses the 
Anatomical Therapeutic Chemical Classification System (ATC) and contains data on all 
dispensed prescription drugs for each patient throughout the country (327).  
The Swedish Heart Failure registry (SwedeHF) or RiksSvikt was founded in 2000, has 
nationwide coverage and is managed by Uppsala Clinical Research Centre. The registry is 
implemented in the whole of Sweden and registers clinically diagnosed heart failure from 70 
out of 80 hospitals and 100 out of 1000 primary care facilities (328). The clinically diagnosed 
term refers to the fact that it only requires a physician’s assessment as heart failure to be 
added in the heart failure registry and ECHO or other investigations are not mandatory. 
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Reporting in the registry is voluntary and ejection fraction is recorded for about 90% of the 
cases (328). It is estimated that the registry covers 54% of prevalent inpatient heart failure 
cases but coverage for incident heart failure is only 9.5% (both in- and out-patient) (328, 
329).  
 
The PANTHER trial 
Data source for Papers II-IV was the Pan-European Tailored Chemotherapy (PANTHER) 
trial. This academic international, multicentre, open-label, randomised phase III trial enrolled 
patients in 86 centres in Sweden, Germany and Austria between 2007 and 2011 (92). In 
summary, women between 18 and 65 years old, in good physical condition (ECOG PS 0-1), 
with radically resected high-risk early breast cancer; lymph node positive or high-risk node-
negative (defined as younger than 35 years old or tumour larger than 2 cm with histological 
grade 3 and hormone receptor negativity). Patients with distant metastases or prior history of 
major cardiovascular disease were not eligible for inclusion in the trial. Random allocation 
1:1 to the experimental or the standard treatment schedule was performed (figure 13). In total 
1006 women were allocated to receive tailored dose-dense chemotherapy and 1011 to receive 
standard treatment (n=2017).  
 
 
 
Figure 13. Description of the design of the PANTHER trial.  Adjuvant trastuzumab for  
one year was administered after completion of chemotherapy or concomitant with docetaxel.  
N= node, q3w= every three weeks, R= randomisation. Courtesy Dr Theodoros Foukakis 
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The standard treatment group received three cycles of standard FEC administered every three 
weeks (F 500 mg/m2, E 100 mg/m2, C 500 mg/m2) followed by three cycles of docetaxel 100 
mg/m2 every three weeks. The experimental treatment group received four cycles of tailored 
and dose dense chemotherapy epirubicin (38-120 mg/m2, starting at 90 mg/m2) and 
cyclophosphamide (450-1200 mg/m2, starting at 600 mg/m2) every two weeks (EC), followed 
by four cycles of tailored and dose dense docetaxel, (75-100 mg/m2, starting at 75 mg/m2) 
every two weeks. In the case of HER2 positive breast cancer, adjuvant trastuzumab was 
administered for one year, according to international guidelines. Trastuzumab started initially 
after accomplishment of all adjuvant chemotherapy and after October 2007, trastuzumab was 
recommended to begin in conjunction with docetaxel. Chemotherapy dose in the 
experimental group was tailored according to protocol-predefined guidelines according to 
haematological toxicity on day 8, 11/12 and 14/15, based on retrospective data indicating 
survival benefit for patients that developed severe haematological toxicity (330, 331). In 
addition, the protocol also predefined possibility for dose modification in case of severe non-
haematological toxicity; namely diarrhoea, stomatitis, fatigue, neuro- and liver toxicity. 
Efficacy results after a median follow-up of 5.3 years (interquartile range [IQR] 4.5 – 6.1 
years) were published in 2016 (92). 
The PANTHER phase III trial was approved by ethics committees in the different regions and 
relevant competent authorities in Sweden, Germany and Austria and procedures relevant to 
the projects of the thesis are in concordance with current laws of Sweden and the Helsinki 
declaration. All patients included in the PANTHER trial provided written informed consent. 
Information recorded on the case-report forms of the trial and specific study-related 
echocardiograms were collected for the purposes of the current thesis.  
 
Cardiac safety sub-study 
A subset of patients from the PANTHER trial enrolled at the Swedish sites of Stockholm, 
Lund/Malmö and Umeå were asked to participate in the sub-study investigating safety of 
trastuzumab when tailored dose-dense chemotherapy is administered. Patients with HER2 
positive breast cancer and equal number of control patients with HER2 negative breast 
cancer, matched for age, treatment group and institution were included. All patients provided 
separate informed consent for the sub-study. ECHO or MUGA, related biomarkers, cardiac 
medication and NYHA classification are registered at baseline, 4-, 6- and 10-years follow-up. 
The study obtained approval by the regional ethics committee in Stockholm and all study-
related procedures followed current Swedish legislation and the Helsinki declaration. 
 
3.2  Study population 
 
Paper I 
For the purpose of paper I, the SwedeHF registry was scrutinised to identify women with 
heart failure that were reported in the registry between 2008 and 2013. Of the 17 540 women 
identified, 2539 were excluded due to previous cancer diagnosis other than breast cancer, 
based on information from the Swedish Cancer Registry. Finally, 14 998 women were 
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deemed eligible for further investigation. Of these, 632 had been previously diagnosed with 
breast cancer. For the formation of the study cohort a selection was made on a 1:5 matching: 
for every person with heart failure and known breast cancer history five controls matched for 
age were selected. Finally, n= 3792 women with heart failure were included in the analysis of 
which n=632 also had prior history of breast cancer and n=3 160 did not.  
Demographic characteristics, clinical signs and symptoms related to heart failure, NYHA 
classification and potential comorbidities, heart failure treatment, history of cancer and cause 
of death were collected from the registries. In addition, available results from ECG, ECHO 
and biochemical tests related to heart failure were registered. The data was additionally cross-
referenced to the Cause-of-Death registry for the purpose of cause-specific survival analysis.  
 
Paper II 
Papers II-IV investigated different subpopulations of the women enrolled in the PANTHER 
phase III trial described earlier. For the intention-to-treat efficacy analysis of adjuvant 
trastuzumab in combination to tailored dose-dense chemotherapy versus trastuzumab and 
standard chemotherapy, population of interest was all patients with HER2 positive breast 
cancer (N=342). 
The prospective, observational cardiac safety sub-study enrolled patients in the PANTHER 
trial treated in Sweden (n=157).  In total 78 women with HER2 positive and 79 women with 
HER2 negative breast cancer were included.  
 
Paper III 
All patients participating in the PANTHER phase III trial that received at least one cycle of 
chemotherapy were included (n=2000); 1001 patients received tailored dose dense 
chemotherapy and 999 received standard chemotherapy. The PANTHER trial database and 
original case report forms (CRFs) were the source of information on the use of G-CSF, 
neutropenia and infection-related complications, treatment delays and dose reductions before 
and after each cycle.  
For the patients treated with tailored and dose-dense chemotherapy, primary prophylaxis with 
G-CSF was mandatory. The type of G-CSF to be used was not pre-specified and both 
pegfilgrastim and filgrastim (or biosimilars) were administered. The study protocol mandated 
pegfilgrastim to be administered as single dose on day 2. Filgrastim was administered on 
days 4-11 during the first part of the adjuvant treatment with tailored dose-dense epirubicin 
and cyclophosphamide and on days 4-10 during docetaxel. Importantly, the tailored dose-
dense chemotherapy group also received primary prophylaxis with antibiotics (ciprofloxacin 
500 mg b.i.d on days 5-12) during EC. During docetaxel, ciprofloxacin was recommended 
only as secondary prophylaxis.  
Initially, the protocol did not include guidelines for primary G-CSF prophylaxis for patients 
treated in the standard chemotherapy group and secondary prophylaxis was recommended in 
case of absolute neutrophil count less than 1.5 x 109/L or febrile neutropenia. However, in the 
summer of 2010, after interaction with the Independent Data Safety and Monitoring 
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Committee following a pre-planned safety analysis this policy changed. The protocol 
recommended then primary prophylaxis with G-CSF even for patients treated with standard 
chemotherapy schedule, but it was still not mandatory. The decision was communicated to 
the investigators on June 18th 2010. 
 
Paper IV 
The case report forms of the PANTHER trial were examined to identify menopausal status of 
trial participants at baseline. In total 1913 participants with available menopause status at 
baseline were identified and included in the current paper; n=956 from the tailored dose-
dense chemotherapy group and n=957 from the standard chemotherapy group. Further data 
from the trial database were retrieved regarding menopausal status at two years follow-up, 
administered endocrine therapy, use of GnRHa and breast cancer outcome data.  
 
3.3 The common terminology criteria for adverse events (CTC AE) 
“An adverse event is any unfavourable sign, symptom or disease temporally associated with 
the use of medical treatment that may or may not be related to the medical treatment or 
procedure” (332). In the controlled environment of clinical trials, registration of adverse 
events (AEs) is a prerequisite to ensure safety of the trial participants as well as to gain 
knowledge on safety issues of the drugs under investigation. Severity of the reported adverse 
events is graded on a scale from 1 to 5, with 5 related to AEs with fatal outcome. Grade 1 
refers to mild AEs, usually asymptomatic and not requiring intervention and grade 2 AEs are 
of moderate severity and can require low scale interventions. More severe AEs are graded as 
grade 3 if they are severe, require interventions, limit possibility for self-care activities but are 
not considered life-threatening and grade 4 are severe, life-threatening conditions that require 
urgent action. CTC AE version 3.0 was applied for registration of AEs in the PANTHER trial 
and has been utilised for the purpose of paper III (table 4). Neutropenic events in paper III 
included FN according to CTC AE version 3.0 and infection with neutropenia (ANC < 1.0 
x109/L).  
 
3.4 Echocardiography and MUGA  
Reported LVEF in papers I and II are based on estimations from echocardiography (ECHO) 
or multigated acquisition scan (MUGA), depending on the centre. The normal ranges of 
LVEF vary slightly between genders but in general, LVEF 50% or above is considered as 
normal and this has also been the cut-off used for inclusion in the PANTHER trial. 
The ECHO is a non-invasive test and therefore participants do not risk any harm but is 
subjected to inter-operator variations. There are various methods of visualisation and 
calculation of LVEF with the most recommended one today being the modified Simpson’s 
biplane method, a two-dimensional method but in praxis both the latter and visual estimations 
are applied. The modified Simpson’s method uses both four-chamber and two-chamber views 
to trace endocardial border in end-systole and end-diastole. 
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Table 4. Grade of selected adverse events related to bone marrow toxicity, according to the Common Terminology 
Criteria for Adverse Events (CTC AE) version 3.0 (published August 2003). 
 
MUGA is also non-invasive, however small amount of radioisotope is injected intravenously, 
which may cause pain and discomfort to the patient. This method also exposes the patient to 
non-ionising radiation, which is less appealing for repeated measurements and is currently not 
widely performed. MUGA is considered to be less subjective to inter-observer variations but 
different computer processing programmes and different centres can still impact 
heterogeneity in the measurements (333). Additionally, since MUGA is based on imaging 
projection, it can be subject to systematic errors. 
Ejection fraction actually represents the fraction of the volume of blood in the left ventricle 
ejected in systole (stroke volume, SV) in relation to the volume of the same chamber at the 
end of diastole (end-diastolic volume, EDV). Stroke volume is estimated by subtraction of 
end-systolic volume (ESV) of the left ventricle from the end-diastolic volume (EDV-ESV). 
Thus, LVEF can be calculated from: 
LVEF = [(EDV-ESV)/EDV] x 100 or LVEF=[SV/EDV] x 100 
 
3.5 Statistical analysis  
To better characterise study population in Paper I and to facilitate statistical comparisons, the 
Swedish National Hospital Discharge Register was examined to identify date of heart failure 
diagnosis. The date of inclusion in the heart failure registry was considered as index date. If a 
patient had been registered in the SwedeHF registry within 1 month from the registered date 
of heart failure diagnosis, she was classified as “incident heart failure” whereas enrolment 
after more than 1 month from heart failure diagnosis was classified as “prevalent heart 
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failure”. The distinction between incident and prevalent heart failure was thereafter utilised 
for group comparisons.  
In Papers II and IV, time for event-free patients was calculated from date of randomisation 
(start date) until the date of last clinical visit (end date).  
The primary endpoint of Paper II was breast cancer relapse-free survival (BCRFS) defined 
as time from randomisation to breast cancer relapse or breast-cancer specific death. 
Secondary outcomes of overall survival (OS), event-free survival (EFS) and distant disease-
free survival (DFS) were defined as follows: i) OS: time to death by any cause, ii) EFS: 
defined as time to breast cancer relapse, contralateral breast cancer, any other malignancy or 
death, regardless cause, iii) DFS: time to distant metastases or death due to breast cancer.  
In Paper III, no direct comparison of neutropenia incidence between the two treatment 
schedules was performed upon two main reasons. Firstly, because almost all patients treated 
with tailored dose-dense chemotherapy received primary prophylaxis with G-CSF, in 
adherence to the study protocol. Secondly, because in the specific group more chemotherapy 
cycles were delivered (8 versus 6 in the standard chemotherapy group) leading to a baseline 
increased risk of neutropenia and thereby not directly comparable to the standard treatment 
group. Although primary prophylaxis even in the standard group was communicated as per 
June 16th 2010, the 1st of August 2010 was defined as dichotomous date, permitting adequate 
time for the information to reach the investigators and be incorporated at the study centres. 
The primary objective of Paper IV was BCRFS, as defined above, per menopause status 
subgroups analysis per breast cancer subtype. The secondary endpoint was to examine 
incidence of CIA, defined as cessation of menstruation after chemotherapy and up to two 
years of follow-up, among patients that were premenopausal at breast cancer diagnosis and 
did not receive GnRHa. 
Baseline characteristics of the population of each paper were described as absolute numbers 
and percentages for categorical variables. Means were instead presented for continuous 
variables and age was presented as median. T-test was applied for comparison between 
groups of continuous variables and Fisher’s exact test or χ2 test were performed for 
comparisons of categorical variables. No corrections for multiple testing were performed. A 
5% significance level was chosen for two-sided tests. 
Results from randomised trials can suffer from missing data or protocol violations. Two 
approaches to address the latter is to analyse data by extracting data from patients that did not 
comply to the protocol (per protocol analysis, PP) or include all patients and analyse data 
according to the group the patients were randomised in (intention to treat analysis, ITT). The 
ITT analysis is more conservative, aiming to minimise introduction of potential bias by 
excluding patients from the analysis. On the other hand, PP analysis is more prone to give the 
efficacy measurements in ideal conditions, reducing bias by false treatment and protocol 
violations. ITT is a more complete analysis and data from every patient included in the trial is 
analysed, with the exception of patients that no data is available or they did not receive any 
treatment at all. An ITT approach has been applied for the purposes of paper II-IV. 
Survival analysis investigates the time from a specified start point until the occurrence of an 
event of interest. The time from start to the event is referred to as survival time. Even though 
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death is usually the event of interest, the analysis can be used for various types of events that 
can be defined with certainty. Such examples in oncology can be time to disease progression 
and type to cancer relapse (local or metastatic).  
The Kaplan-Meier (KM) curve is a non-parametric method commonly used to visualise 
survival and to estimate probability of survival over time. Individuals that prematurely finish 
their follow-up for reasons other than the study endpoints (e.g. due to loss to follow-up), are 
being censored but the time until the last known follow-up visit can be accounted in the 
analysis. However, some basic assumptions are required for the use of KM; that the censored 
patients have the same probability of survival as those still in the study, that survival 
prospects are the same regardless time of inclusion and that the expected event happens 
within a specific time period. In paper I the KM-curve was applied to visualise and calculate 
cumulative incidences for death due to any cause, death due to cardiovascular disease and due 
to heart failure in four different groups; incident heart failure +/- breast cancer history and 
prevalent heart failure +/- breast cancer history. In papers II and IV reverse KM-curve (1-
KM) was utilised to estimate median follow-up time. Median follow-up time is defined as the 
follow-up time where the KM-function is less than or equal to 0.5. 
Another method utilised in survival analysis context is the Cox regression (or proportional 
hazards regression) for survival analysis that estimates the effect of different variables on the 
time-to event. Despite being regarded as non-parametric, this method assumes that variables 
affecting survival are constant over time. The Cox regression survival analysis was applied 
for estimation of time to failure, hazard ratios and 95% confidence intervals.  
Even though the Kaplan Meier curve is widely applied in cancer research, in the presence of 
competing risk for other events, this method can overestimate the cumulative probability of 
an event (cause-specific failure). Competing risks are events that can alter the probability of 
the occurrence of the event of interest. To provide some examples in the context of breast 
cancer research, development of second primary cancer or death due to causes other than 
breast cancer can be considered as competing risks, if the endpoint of interest is breast cancer 
relapse or death. Therefore, for the purposes of the survival analysis in paper II, cumulative 
incidence curves were applied for estimation of breast cancer outcomes. This function takes 
into consideration the fundamental contribution of other causes (competing risks) in the 
overall outcome. 
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RESULTS 
Paper I – Outcome and Presentation of Heart Failure in Breast Cancer patients: 
Findings from a Swedish Register-based Study. 
This registry-based study investigated differences in clinical presentation of heart failure, 
received heart failure care and survival in women with heart failure with and without 
previous breast cancer history.  
In total, 1764 women with incident heart failure (iHF) (of which 294 with breast cancer 
history) and 2028 with prevalent heart failure (pHF) (338 with previous breast cancer) were 
included in the analysis with a median follow-up time of 2 years. Median time from breast 
cancer (BC) diagnosis to heart failure diagnosis was 6.2 years (IQR 3.3 – 8.4 years). Table 5, 
describes baseline characteristics of these individuals.  
Cardiovascular risk factors did not differ significantly between the four groups (iFH, iHF + 
BC, pHF, pHF + BC). Interestingly, all groups reported mean BMI that falls in the 
overweight range, around 27 kg/m2. In addition, a little more than half of the patients in each 
group had hypertension, without any significant interaction with breast cancer diagnosis or 
time from heart failure diagnosis. No differences were present regarding smoking habits and 
presence of diabetes mellitus. 
Overall, no statistically significant variations were seen in cardiovascular risk factors, pre-
existing comorbidities, clinical features and heart failure care among patients with and 
without breast cancer, in the group classified as iHF. However, some small deviations were 
noticed in the management of patients with pHF. As presented in table 6, incidence of history 
of myocardial infarction among patients with pHF was significantly lower among patients 
with breast cancer history; 21.6% vs. 28.6%, p<0.01. Fewer patients with pHF and breast 
cancer history had undergone coronary revascularization (11.8% vs. 16.2%, p<0.01) or were 
prescribed aspirin (47.6% vs. 55.1%, p=0.01) compared to those without previous breast 
cancer. Although device therapy was not commonly applied in any of the groups, patients 
with pHF and BC history were significantly less frequently treated with implantable 
cardioverter-defibrillators and cardiac resynchronisation therapy than patients with only pHF; 
0.6% vs. 1.6 % and 0.9% vs. 3% respectively. 
Within group comparisons did not show any impact on the cumulative incidence for all-cause 
mortality, cardiac mortality and mortality due to heart failure at 1-, 2- and 5-year follow-up in 
any of the groups (figure 14). On the other hand, inter-group comparison revealed increased 
mortality on every endpoint in the pHF group. In both groups, mortality rates increased with 
time, for example 1-year all-cause mortality for iHF with breast cancer was 15.3% compared 
to 43.2% 5-year all-cause mortality for the same group.  
In conclusion, history of breast cancer diagnosis did no significantly impact aetiology and 
survival of heart failure nor overall survival among patients with established heart failure. In 
the group of women with longer duration of heart failure (pHF) some differences were seen 
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in regards of myocardial infarction incidence and heart failure management depending on 
breast cancer history status. 
 
 
Table 5. Baseline characteristics of women registered in the SwedeHF registry according to time from heart failure 
diagnosis to inclusion in SwedeHF and presence or not of breast cancer history. BC: breast cancer, HF: heart failure, 
IQR: interquartile range, NA: not available 
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Table 6. Pre-existing comorbidities and treatment for the women with heart failure included in the study. BC: 
Breast cancer, HF: heart failure 
 
Figure 14. Cumulative incidence of heart failure specific mortality among patients included in the study.  
BC: breast cancer, HF: heart failure.  
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Paper II – Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy 
and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 
3 PANTHER Trial. 
The aim of this study was to investigate efficacy and safety of trastuzumab in combination 
with tailored and dose-dense adjuvant chemotherapy. 
Trastuzumab exposure and efficacy analysis 
There were 342 HER2-positive patients enrolled in the PANTHER phase III trial of which 
182 were treated with standard and 160 with tailored dose-dense chemotherapy. Median 
follow-up for the analysis was 5.3 years (IQR 4.4 – 6.3 years). Three hundred thirty-five 
patients received at least one dose of trastuzumab. Three patients withdrew consent, two were 
lost to follow-up and two more did not receive any trastuzumab due to other reasons, with 
balanced numbers between the treatment groups. Median age and tumour-related baseline 
characteristics were balanced between the standard therapy and tailored dose-dense 
chemotherapy and are presented in table 7. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Clinical baseline characteristics of patients 
with HER2 positive breast cancer in the PANTHER 
phase III trial. ER: oestrogen receptor, PR: 
progesterone receptor 
 
 
Table 1. Baseline characteristics of the HER2-positive patients  
randomized in the PANTHER trial 
    
  Standard 
chemotherapy 
 
N=182 (%) 
Tailored dose-
dense 
chemotherapy 
N=160 (%) 
 
   
     
Median age, years 
(range) 
48.3 (21.4-66.4) 51.5 (28.0-69.5) 
     
Tumor size, mm     
0-20 73 (40.1) 61 (38.1) 
21-50 92 (51.5) 87 (54.4) 
>50 17 (9.3) 12 (7.5) 
     
Positive nodes      
0 6 (3.3) 6 (3.8) 
1-3 99 (54.4) 89 (55.6) 
4-9 53 (29.1) 43 (26.9) 
>9 24 (13.2) 22 (13.8) 
     
Tumor grade     
I 0 (0.0) 3 (1.9) 
II 64 (35.2) 46 (28.7) 
III 118 (64.8) 110 (68.8) 
Missing 0 (0.0) 1 (0.6) 
     
Hormone receptors     
ER and/or PR (+) 109 (59.9) 105 (65.6) 
ER and PR (-) 73 (40.1) 55 (34.4) 
     
Ki-67 %     
≤20 33 (18.1) 27 (16.8) 
>20 96 (52.7) 85 (53.1) 
Missing 53 (29.1) 48 (30.0) 
     
Trastuzumab     
Administered 175 (96.2) 155 (96.9) 
Not administered 7 (3.8) 5 (3.1) 
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In total 15 out of 29 patients discontinued trastuzumab prematurely due to cardiotoxicity; 10 
in tailored dose-dense group and 5 in standard group. One patient had persistently low LVEF 
after 3 years, whereas three patients did not perform other evaluations and two died due to 
metastatic disease. Of the remaining nine, two patients reported recovered LVEF at one year 
follow-up, three at two years, two at three years and two at five years. Other reasons for 
trastuzumab discontinuation were disease progression (n=4), and other reasons (n=10).  
The combination of dose-dense chemotherapy and trastuzumab led to a non-significant 
relative reduction of the risk for breast cancer relapse by 32% compared to standard treatment 
(HR=0.68, 95% CI 0.37 – 1.27, p = 0.231), as presented in figure 15. In absolute numbers, 16 
versus 26 breast cancer relapse events were reported in the tailored dose-dense and standard 
chemotherapy group respectively, in an intention to treat analysis. The 5-year breast cancer 
relapse-free survival was 89.1% and 85.3% respectively with an absolute gain of 3.8% (95% 
CI 3.7% – 11%). No significant interaction between treatment efficacy and hormone receptor 
status was demonstrated and similar trends were noted for all secondary endpoints. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Breast cancer relapse-free survival (A) and overall survival (B) for patients with HER2 positive 
breast cancer treated with standard or tailored dose-dense chemotherapy in the PANTHER phase III trial. 
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Cardiac outcomes HER2 positive versus HER2 negative 
Among the patients enrolled in the PANTHER trial in Sweden (n=780), 176 were assessed 
eligible to be included in the cardiac safety sub-study and finally 157 consented to participate. 
Figure 16, depicts the Consolidated Standards of Reporting Trials (CONSORT) diagram of 
the PANTHER HER2 cardiac safety sub-study. Baseline characteristics between the HER2 
positive group and the matching control group were not entirely balanced. Median age, 
tumour sidedness and delivered chemotherapy were in balance but the groups differed in 
regards of hormone receptor status and received radiotherapy (table 8). The numbers were 
balanced in regards of allocated chemotherapy treatment and the mean epirubicin doses were 
similar; 346.1 mg/m2 in the HER2 positive group and 344.4 mg/m2 in the control group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Consolidated Standard of Reporting Trials diagram of the PANTHER HER2 cardiac safety sub-
study. DD: Tailored dose-dense chemotherapy. SD: Standard chemotherapy. 
 
 
 
 
2017 patients randomized
in the Pan-European Tailored Chemotherapy [PANTHER] study
(n=2003 in the primary intention-to-treat analysis)
342 HER2-positive
5 did not receive trastuzumab
- 3 withdrew consent
- 2 other reasons
2 patients lost to follow-up
       SD (n=182)
       DD (n=160)
1660 HER2-negative
1 missing data
342 included in the intention-to-
treat analysis
780 patients included in Sweden
Analyzed 4 years (n=76)
SD (n=43)
DD (n=33)
Assessed for eligibility in the 
cardiac safety sub-study (n=176)
Included (n=157)
Analyzed 4 years (n=77)
SD (n=42)
DD (n=35)
Analyzed 6 years (n=76)
SD (n=43)
DD (n=33)
Analyzed 6 years (n=75)
SD (n=40)
DD (n=35)
HER2 negative (n=79)
SD (n=43)
DD (n= 36)
HER2 positive (n=78)
SD (n=43)
DD (n=35)
2017 patients randomized
in the Pan-European Tailored Chemotherapy [PANTHER] study
Excluded due to relapse (n=1)Excluded due to relapse (n=3)
Excluded due to relapse (n=1)
Other reason (n=1)
BA
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Normal cardiac function at inclusion, according to ECHO or MUGA, was required to fulfil 
eligibility criteria for the PANTHER phase III trial. In the sub-study, mean baseline LVEF 
was similar in the two groups; 61.2% for the HER2 positive group and 62.5% for the HER2 
negative group.  At four years follow-up, four patients were excluded due to breast cancer 
relapse. Mean LVEF did not differ between groups for the remaining n=153; 58.7% HER2 
positive and 59.9% HER2 negative. Accordingly, at 6-years follow-up, n=151 patients were 
investigated. Mean LVEF and difference from baseline was similar between the groups and 
even though it had declined from baseline, mean LVEF remained within normal range; 
58.8% among patients treated with trastuzumab and 59% among those who did not. Both at 
4- and 6-years follow-up, LVEF drop of 10% or higher, was comparable between the groups 
(table 9). Additionally, reported electrocardiographic abnormalities, NYHA classification, 
prescription of cardiac medication, frequency of hypertension or diabetes mellitus and levels 
of cardiac biomarkers were similar between the treatment groups and not clinically or 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Baseline characteristics of HER2 
positive and HER2 negative groups in the 
PANTHER cardiac safety sub-study. ECG: 
Electrocardiogram; ECHO: 
Echocardiography; ER: Oestrogen receptor; 
LVEF: Left ventricular ejection fracture; 
MUGA: multigated acquisition; PR: 
Progesterone receptor. 
 
 
Supplementary Table S1. Baseline characteristics of the patients included in 
the cardiac safety sub-study 
 
ECG: Electrocardiogram; ECHO: Echocardiography; ER: Estrogen receptor; LVEF: 
Left ventricular ejection fracture; MUGA: multigated acquisition; PR: Progesterone 
receptor 
 HER2 positive 
N=78 (%) 
HER2 negative 
N=79 (%) 
P value  
      
      
Median age, years 
(range) 
51.5 (28.4 – 64.7) 50.6 (29.1 – 64.9) 0.58 
      
Center     0.92 
Umeå 32 (41.0) 30 (38.0)  
Lund 9 (11.5) 9 (11.4)  
Stockholm 38 (47.4) 40 (50.6)  
      
Side     0.75 
Right 34 (43.6) 37 (46.8)  
Left 44 (56.4) 42 (53.2)  
      
Chemotherapy      1.0 
Tailored dose-dense 35 (44.9) 36 (45.6)  
Standard 43 (55.1) 43 (54.4)  
      
ER     0.02 
Positive 50 (64.1) 64 (81)  
Negative 28 (35.9) 15 (19)  
      
PR     <0.001 
Positive 37 (47.4) 62 (78.5)  
Negative 41 (52.6) 17 (21.5)  
      
ECG     0.49 
Normal 73 (93.6) 74 (93.7)  
Abnormal 5 (6.4) 3 (3.8)  
Not done 0 (0.0) 2 (2.5)  
      
Radiotherapy     0.03 
Local 16 (20.5) 25 (31.7)  
Loco-regional 48 (61.5) 52 (65.8)  
Not given 14 (18) 2 (2.5)  
      
MUGA/ECHO     0.18 
Mean LVEF 61.19 % 62.47 %  
Missing 3 (3.8) 2 (2.5)  
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Table 9. Left ventricular ejection fraction changes at baseline, 4- and 6-years follow-up in the PANTHER 
cardiac safety sub-study according to HER2 status and delivered chemotherapy. FEC/D: standard 
chemotherapy 5-fluorouracil/epirubicin/cyclophosphamide and docetaxel, HER2: Human Epidermal growth 
factor Receptor 2, LVEF: Left Ventricular Ejection Fraction, tDD EC/D: tailored and dose dense 
epirubicin/cyclophosphamide and docetaxel 
 
 
Cardiac outcomes tailored dose-dense versus standard chemotherapy 
A predefined comparison of LVEF decline between the two treatment schedules revealed 
statistically lower LVEF among patients treated in the tailored dose-dense group, even though 
mean LVEF remained within normal range. Moreover, at 4-years follow-up there was a 
statistically significant LVEF decline within both treatment schedules (p<0.01 for both 
groups). Similar decline was seen at 6-years follow-up within the tailored dose-dense group 
(p<0.001). None of the observed LVEF declines responded to clinically relevant findings. 
Higher mean epirubicin dose in the tailored dose-dense group (400.5 mg/m2) compared to the 
standard chemotherapy group (296.3 mg/m2) did not translate to increased cardiotoxicity. 
In summary, trastuzumab in combination with tailored dose-dense chemotherapy showed a 
trend to improved breast cancer outcomes, though not significantly. There was no direct 
impact on cardiotoxicity following trastuzumab administration. 
 
 
Table 2. Left ventricle ejection fraction at baseline, at four- and at six- years follow-up in relation to received chemotherapy with and 
without trastuzumab 
 
 Trastuzumab 
whole cohort 
Trastuzumab 
FEC/D 
Trastuzumab  
tDD EC/D 
 No 
trastuzumab 
Whole cohort 
No 
Trastuzumab 
FEC/D 
No Trastuzumab  
tDD EC/D 
        
 N=78 N=43 N=35  N=79 N=43 N=36 
        
Baseline         
Mean LVEF 61.2 % 61.7 % 60.6 %  62.5 % 62.6 % 62.4 % 
        
4-years follow up        
Mean LVEF 58.7 % 58.3 % 59.2 %  59.9 % 61.2 % 58.1 % 
        
LVEF value drop ≥ 
10% 
11 (14.3 %) 
 
7  4   10 (13.2 %) 4 6 
        
Mean difference from 
baseline 
2.3 % 0.6 % 3.5%  2.6 % 1.6 % 4.1 % 
        
6-years follow up        
Mean LVEF  58.8 %  59.5 % 57.8 %  59 % 61.8 % 55.8 % 
        
LVEF value drop ≥ 
10%  
12 (16 %) 7 5  11 (16.6%) 5 6 
        
Mean difference from 
baseline 
2.4 % 2.2 % 2.6 %  3.4 % 0.7 % 6.6 % 
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Paper III – Neutropenic Complications in the PANTHER phase III study of Adjuvant 
Tailored Dose-Dense Chemotherapy in Early Breast Cancer. 
Utility of G-CSF and neutropenic complications in the PANTHER trial were investigated in 
this secondary, retrospective study. 
Among the 2000 patients administered at least one chemotherapy cycle, 1001 were treated 
according to the tailored dose-dense schedule and 999 according to the standard schedule. As 
per protocol recommendation, the majority of the patients in the former group received 
primary prophylaxis with G-CSF (98.9% during EC and 97.4% during docetaxel) whereas in 
the latter group about half the patients received primary prophylaxis; 49.7% during FEC and 
63.8% during docetaxel (D). As noted in table 10, pegfilgrastim was the most popular G-CSF 
administered in the PANTHER trial, although the choice of which G-CSF to use was left on 
the physician. An exploratory analysis on the efficacy of pegfilgrastim versus filgrastim did 
not show any statistically significant difference.  
Among the patients treated with standard chemotherapy schedule, 5.4% during FEC and 
6.3% during D developed grade 3-4 neutropenic events respectively. In comparison, despite 
provision for prophylactic G-CSF, 7% during tailored dose dense EC and 1.6% during 
docetaxel reported such events. Rate of infection with normal ANC was similar among 
patients treated with anthracyclines, regardless dose intensity, and standard docetaxel, 
ranging between 2.5% and 3.7%. On the other hand, tailored dose dense docetaxel was 
related to more infections with normal ANC (7.4%), although the same group developed 
fewer events of infection accompanied with neutropenia (0.8%). Notably, neutropenic 
complications were not related to any grade 5 toxicity (death) in the study.  
 
Table 10. Type of G-CSF used in the PANTHER phase III trial. EC: epirubicin, cyclophosphamide, FEC: 5-
fluorouracil, epirubicin, cyclophosphamide, G-CSF: granulocyte-colony stimulating factor, tdd: tailored dose-
dense 
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Administration of G-CSF reduced the risk of neutropenic events overall (odds ratio, OR 0.44, 
95% CI 0.35 – 0.55) and more specific in the standard chemotherapy group, change of 
prophylaxis policy led to significantly fewer grade 3 or 4 neutropenic events (OR 0.48, 95% 
CI 0.31 – 0.73).  
Compliance to planned treatment according to protocol and delays or dose reductions due to 
neutropenia were calculated per chemotherapy cycle. A total of 13 343 chemotherapy cycles 
were delivered in the study, of which 10 391 with G-CSF support and 2950 without. The risk 
for febrile neutropenia was significantly increased in the absence of G-CSF support whereas 
the overall risk for infection was not affected by G-CSF administration despite a significant 
disparity on the risk of infection depending on ANC levels. The risk for grade 3-4 infection 
with low ANC was significantly higher among patients that did not receive G-CSF support 
compared to those who did but the opposite was observed for infection with normal ANC, as 
described in table 11.  
Overall, 5.6% (n=753) of planned chemotherapy cycles were delayed of which more than 
half was due to administrative or other reasons. Delays related to leukopenia and/or infections 
were distributed as follows: 131 were delayed due to infection, 114 due to neutropenia 
(n=114), 51 due to leukopenia and 16 due to neutropenic fever. Chemotherapy cycles among 
patients treated in the standard chemotherapy group were more likely to be delayed (3.3%) 
compared to the tailored dose-dense regimen (2.6%) even though a formal statistical 
comparison was not performed. Administration of G-CSF support significantly reduced risk 
of delay for the subsequent chemotherapy cycle due to neutropenia (OR 0.098, 95% CI 0.06 – 
0.15) or leukopenia (OR 0.32, 95% CI 0.18 – 0.58). This became more obvious when the 
policy change for G-CSF support in the standard chemotherapy group resulted in reduction of 
the risk for chemotherapy delay due to neutropenia (OR 0.52, 95% CI 0.32 – 0.84). Dose 
reductions overall in the standard chemotherapy group were very low; 165 out of a total of 
5705 cycles were reduced in dose due to neutropenic event, infection with normal ANC and 
neutropenia or leukopenia. Dose reductions in the tailored dose dense therapy group were 
protocol predefined and were therefore not considered for this analysis. 
 
 
Table 11. Neutropenic events (febrile neutropenia and infection with low ANC) and infection with normal ANC with and 
without G-CSF. ANC: Absolute neutrophil count, G-CSF: granulocyte-colony stimulating factor, OR: odds ratio, CI: 
Confidence interval. Grade reported according to CTC AE v 3.0. 
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In conclusion, tailored dose-dense chemotherapy with G-CSF support did not increase 
haematological toxicity. Administration of G-CSF reduced neutropenic events and allowed 
for better compliance on the planned treatment schedule. 
 
Paper IV – Incidence of Amenorrhea and Impact on Breast Cancer Outcomes During 
Tailored Dose Dense Chemotherapy for High-Risk Early Breast Cancer. 
The aim of this post-hoc study was to examine whether gonadal toxicity related to tailored 
and dose dense chemotherapy can impact breast cancer related outcomes and if menopause 
status at breast cancer diagnosis can impact chemotherapy efficacy on high-risk early breast 
cancer outcomes.  
This retrospective, exploratory analysis included 1913 participants in the PANTHER trial 
with available menopause status at baseline; 1036 were premenopausal and 877 were 
postmenopausal at inclusion. Figure 17 presents distribution of patients in the treatment 
groups based on baseline menopausal status and allocated treatment. Treatment allocation 
was balanced between the two different menopause status groups. 
Figure 17. Consolidated Standard of Reporting Trials diagram of the PANTHER HER2 according to baseline 
menopause status and allocated treatment. DD: Tailored dose-dense chemotherapy. ER: Oestrogen Receptor, 
HER2: human epidermal growth factor 2, SD: Standard chemotherapy, TNBC: Triple negative breast cancer. 
 
2017 patients randomised	
in the Pan-European Tailored Chemotherapy [PANTHER] study 	
 
1006 patients 
randomised to 
receive tailored dose-
dense chemotherapy 
 
1011 patients 
randomised to 
receive standard 3-
weekly chemotherapy 
 
9 Excluded 
   7 Withdrew consent 
   2 Lost to follow-up at day 0 
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   4 Withdrew consent 
   1 Lost to follow-up at day 0 
 
515 premenopausal 
       411 ER+ 
       103 ER- 
       79 TNBC 
       81 HER2+ 
       1 unknown ER   
441 postmenopausal 
       355 ER+ 
       86 ER- 
       59 TNBC 
       70 HER2+ 
 
436 postmenopausal 
       345 ER+ 
       90 ER- 
       55 TNBC 
       71 HER2+ 
       1 unknown ER 
521 premenopausal 
       417 ER+ 
       104 ER- 
       68 TNBC 
       104 HER2+ 
 
 1001 Included in the analysis 
45 Unknown menopause 
status 
1002 Included in the analysis 
45 Unknown menopause 
status 
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Baseline characteristics are presented in table 12 and were balanced in terms of tumour size, 
nodal status, hormonal receptor and HER2 status. Imbalance was present regarding tumour 
grade, Ki67 and type of performed surgery. Premenopausal women had higher grade and 
Ki67 tumours and underwent more mastectomies.  
 In total, 251women experienced breast cancer relapse event; 136 premenopausal and 115 
postmenopausal. Overall, tailored and dose dense chemotherapy improved BCRFS regardless 
menopause status but did not reach statistical significance. Compared to standard 
chemotherapy, women treated with tailored dose dense chemotherapy were 17% less likely to 
experience BCRFS event if they were premenopausal (HR 0.83, 95% CI 0.59 – 1.16) and  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. Baseline characteristics of patients enrolled in the PANTHER trial according to menopausal status at 
baseline. ER: Oestrogen receptor; FEC/D: 5-fluorouracil/epirubicin/cyclophosphamide and docetaxel; HER2: 
human epidermal growth factor receptor 2; PR: progesterone receptor; tdd EC/D: tailored dose dense 
epirubicin/ cyclophosphamide and docetaxel 
Table 1. Baseline characteristics of patients randomized in the PANTHER trial with available 
information on baseline menopausal status 
	    
	 Premenopausal patients 
 
N=1036 (%)	
Postmenopausal patients 
 
N=877 (%) 
	
P value	
	 	 	 	 	  
Median age, 
years (range)	
45.2 (21.4 – 65.3)	 58.6 (26.4 – 69.5)	 <0.001 
	 	 	 	 	  
	 	 	 	 	  
Tumor size, mm	 	 	 	 	  
0-20	 424	 (40.9)	 354	 (50.5)	  
0.76 21-50	 538	 (51.9)	 457	 (52.1)	
>50	 69	 (6.7)	 66	 (7.5)	
Missing	 5	 (0.5)	 0	 (0.0)	
	 	 	 	 	  
Positive nodes 	 	 	 	 	  
0	 32	 (3.1)	 28	 (3.2)	  
0.48 1-3	 604	 (58.3)	 488	 (55.6)	
4-9	 284	 (27.4)	 244	 (27.8)	
>9	 116	 (11.2)	 117	 (13.3)	
	 	 	 	 	  
Tumor grade	 	 	 	 	  
I	 64	 (6.2)	 44	 (5.0)	  
0.003 II	 480	 (46.3)	 463	 (52.8)	
III 492 (47.5) 364 (41.5) 
Missing 0 (0.0) 4 (0.5) 
      
Hormone 
receptors 
     
ER and/or PR (+) 828 (80.0) 700 (79.8)  
0.96 ER/PR (-) 207 (20.0) 176 (20.1) 
Missing 1 (0.1) 1 (0.1) 
      
HER2 status      
Positive 185 (17.9) 141 (16.1) 0.30 
Negative 851 (82.1) 736 (83.9) 
      
Ki-67 %      
≤20 288 (27.8) 267 (30.4)  
0.03 >20 373 (36.0) 270 (30.8) 
Missing 375 (36.2) 340 (38.7) 
      
Type of 
operation 
     
Breast 
conserving 
518 (50.0) 502 (57.2) 0.002 
Mastectomy 518 (50.0) 375 (42.8) 
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26% less likely if they were postmenopausal (HR 0.74, 95% 0.51 – 1.06) at the time of breast 
cancer diagnosis. In absolute numbers, experimental treatment improved 5-year BCRFS in 
premenopausal women by 2.5% (-1.8 – 6.8%, p=0.254) and postmenopausal women by 4.6% 
(0.1 – 9.2%, p=0.049). There was no significant interaction between baseline menopausal 
status and allocated treatment. 
At the predefined, for this analysis, two years’ time point, about one third (n=128) of the 
premenopausal women in each group (31.3% in the standard and 32.2% in the experimental 
therapy group) experienced gonadal toxicity and cessation of menstruation (OR=1.04; 95% 
CI 0.77 – 1.39). There was an absolute reduction of BCRFS events among patients that 
experienced chemotherapy-related premature ovarian insufficiency. Forty-eight (8.11%) 
events among women with CIA and seven (12.28%) among those who still menstruated, 
numbers too small to provide power to detect potential benefit.  
Further subgroup analysis per breast cancer subtype revealed statistically non-significant 
reduction of BCRFS events by the experimental treatment among the 1528 patients with 
hormone responsive breast cancer, with or without HER2 amplification. This effect remained 
regardless menopausal status and no formal interaction between efficacy of received 
chemotherapy regimen and menopausal status in hormone receptor positive patients was 
present. Interestingly, among the 261 patients with triple negative breast cancer, a significant 
interaction between treatment and menopausal status was demonstrated (test of interaction 
p=0.043). Tailored and dose dense adjuvant chemotherapy improved BCRFS in 
postmenopausal women (HR=0.44, 95% CI 0.19 – 1.03; p=0.06) but had the opposite effect 
among premenopausal women (premenopausal, HR=1.29, 95% CI 0.69 – 2.40; p=0.426) 
(figure 18). Interaction was present exclusively in the TNBC group and the test of interaction 
was not significant when the entire hormone-receptor negative patients with also HER2 
positive tumours was considered (p=0.155).  
In summary, increased dose intensity did not augment gonadal toxicity. Efficacy of allocated 
treatment was not influenced by the patient’s menopausal status at the time of breast cancer 
diagnosis with the exception of TNBC. A finding that warrants caution and should be further 
investigated, considering the exploratory, not-predefined nature of the analysis. 
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Figure 18. Cumulative incidence for breast cancer relapse-free survival premenopausal versus postmenopausal, 
study population (top) and triple negative breast cancer population (lower) in the PANTHER trial. sFEC-D: 
standard interval 5-fluorouracil/epirubicin/cyclophosphamide and docetaxel; ddtEC-D: tailored and dose dense 
epirubicin/cyclophosphamide and docetaxel; HR: hazard ratio; CI: confidence interval 
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DISCUSSION 
 
Breast cancer is a disease affecting a significant number of women around the globe with 
major bearing on individual, societal and health-economic level. The rapid development in 
breast cancer management and advancements in further understanding disease biology have 
improved survival and increased prevalence of long-term survivors. Despite systemic 
adjuvant anticancer therapies for breast cancer being life-saving, the impact on the person’s 
quality of life and, potentially, survival through serious side effects is not negligible.  
In the current thesis both acute toxicities; neutropenia, infections and acute cardiotoxicity 
during trastuzumab and long-term toxicities such as long-term cardiotoxicity leading to heart 
failure and chemotherapy induced gonadal toxicity were studied. 
 
Paper I 
Management of heart failure nowadays is multifaceted and is directly related to the stage of 
the disease and the symptoms. Paper I utilised the Swedish national registries to compare 
women with heart failure and a breast cancer history to an age-matched female population 
with cardiac insufficiency. No differences were noted between breast cancer survivors and 
general population with reference to heart failure in the iHF group. Despite similarities in 
symptoms and heart failure aetiology, differences in the reported comorbidities and heart 
failure therapies were demonstrated in the pHF group. History of acute myocardial infarction 
(AMI) was more common among women with pHF and no history of breast cancer. A 
finding also consistent with the more frequent utilisation of aspirin or revascularisation that 
was observed in this group.  
Despite imbalance in the history of AMI, women with BC history were as likely to have heart 
failure due to ischemic heart disease as those without. This discrepancy could be either due to 
diagnosis of ischemic heart disease at an early stage before leading to established myocardial 
infarction or most likely due to distinct aetiology of coronary artery disease and ischemia 
among breast cancer survivors. Whether the former stems from increased awareness after 
breast cancer diagnosis or the latter is related to the anticipated distinct ischemic 
cardiomyopathy pathophysiology due to previous chemotherapy and/or radiotherapy cannot 
be assessed in the present paper. Nonetheless, potential bias in expediting investigations and 
monitoring in favour of women with breast cancer history is of importance and merits further 
exploration. 
Age is an important confounder in the risk of both breast cancer and heart failure. The cohort 
was therefore controlled with age-matched population, to adjust for the higher risk of 
cardiovascular disease with increased age. This introduced balance between the groups but 
may have masked potential differences regarding age of onset of heart failure or rate of 
progression between the two groups. 
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Chronic heart failure is a successfully deteriorating condition and thus early detection and 
intervention is essential, not least to prevent sudden worsening leading to acute heart failure 
and decompensation. In line with the progressive course of chronic heart failure, higher 
mortality rates were demonstrated among women with prevalent heart failure (pHF) 
compared to the ones with shorter interval since heart failure diagnosis (iHF), irrespective 
breast cancer history. On the other hand, the median follow-up time of two years might be 
considered short in order to assess potentially distinct heart failure mortality among women 
with breast cancer history and pHF. 
Patients with cancer other than breast cancer were excluded from the analysis, and thus any 
cardiovascular aftereffect is uniquely related to breast cancer therapy. Information on the 
potential breast cancer therapy women in the cohort received or were still receiving after 
heart failure diagnosis would have facilitated evaluation of the results but this data is not 
available in the heart failure registry. Chemotherapy-induced cardiomyopathy and subsequent 
heart failure is often cited to be associated with worse prognosis and a more aggressive 
course than cardiomyopathy of other aetiology such as idiopathic or due to ischemic heart 
disease (334). However, this has been challenged in the recent years due to increased 
awareness and improved heart failure outcomes. Intra-group comparison in the iHP and pHF 
did not reveal any difference in the overall survival or mortality due to cardiovascular disease 
or heart failure between women that had been diagnosed with breast cancer and not. Thus, 
heart failure after breast cancer diagnosis and treatment can likely have the same outcomes as 
heart failure of other causes, if properly and timely addressed.  
 
Paper II 
Increased chemotherapy dose intensity improves breast cancer outcomes (89). Calculation of 
chemotherapy dose regardless inter- and intrapatient pharmacodynamics and 
pharmacogenetic variations faces the risk of over- and undertreatment (96). Individually 
tailoring chemotherapy dose according to levels of maximal bone marrow tolerance, as in the 
PANTHER trial, enables individually adjusted dose levels. Thus, an accepted assumption 
could be that it may also lead to increased cardiotoxicity.  
As previously stated, current guidelines recommend neoadjuvant approach for HER2 positive 
breast cancer and the results from the KATHERINE study, demonstrating meaningful 
improvement of breast cancer outcomes can be considered practice changing (58, 60). In 
consequence, the relevance of optimisation of adjuvant therapy in HER2 amplified breast 
cancer can be questioned. However, implementation of neoadjuvant therapy as such is 
significantly low across countries, even with different economic and health care background 
(335-338). Thus, adjuvant trastuzumab is still extensively exploited and the continuous quest 
for appropriate escalation or de-escalation is justified. 
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Adding chemotherapy, with shorter intervals and individually adjusted doses, to trastuzumab 
in HER2 positive breast cancer led to a non-significant improvement of breast cancer relapse 
by approximately one third, compared to standard backbone chemotherapy. It remains to be 
seen if longer follow-up can lead to significant improvement of breast cancer relapse and 
survival. The subgroup analysis of HER2 positive breast cancer patients treated with adjuvant 
trastuzumab in the GIM2 trial (n=132) did not show statistically significant benefit of 
adjuvant trastuzumab delivered after dose dense chemotherapy over trastuzumab in sequence 
with standard interval chemotherapy (339).  On the contrary, hazard ratio for both DFS and 
OS were close to 1 and with wide confidence intervals. However, this was a post hoc analysis 
of a small portion of a subgroup of the study and without stratification for trastuzumab 
treatment between the two chemotherapy schedules. Similarly, the large meta-analysis by 
EBCTCG showed that trastuzumab did not impact treatment efficacy, however, the use of 
trastuzumab was not standard in half of the included trials (89).  
Molecularly identified HER2 enriched breast cancer by PAM50, could predict better effect in 
terms of higher probability of pCR, after anti-HER2 neoadjuvant therapy (340). On one hand, 
failure to report benefit from dose dense chemotherapy and trastuzumab, could therefore 
derive from dilution of the results by HER2-enriched tumours that respond to anti-HER2 
treatment without particular benefit from intensifying chemotherapy. On the other hand, 
exploration of escalation of chemotherapy would be a logical step forward to improve breast 
cancer outcomes for HER2 non-enriched tumours.  
Trastuzumab in combination to tailored dose dense chemotherapy was safe despite increased 
mean epirubicin dose delivered in the experimental group. That being said, a reduction of 
mean LVEF through time was indeed observed despite lack of clinical relevance. This 
observation suggests a negative long-term undesirable effect of chemotherapy rather than 
trastuzumab. Importantly, there was a significant reduction of LVEF from baseline at six 
years follow-up in the tailored dose dense. This further suggests the observed LVEF decline 
more likely results from the higher mean epirubicin dose administered in the tailored dose 
dense group and underscores the need to investigate whether cardiac function will further 
decline at the planned 10-years follow-up. 
 
Paper III 
The benefit from escalating dose intensity is directly associated with preventing dose 
reductions or delays due to haematological toxicity. Paper III confirmed the undisputable 
prophylactic effect of G-CSF in terms of neutropenia and neutropenic events. G-CSF allowed 
for dose escalation in the experimental group without excess haematological toxicity. On the 
contrary, it must be emphasised that despite higher mean chemotherapy doses delivered in the 
experimental arm, no grade 5 toxicity related to haematological side effects was reported in 
the PANTHER trial. The lack of comparison between the two treatment groups can be 
considered a limitation of the study. This becomes though more understandable if each 
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chemotherapy cycle is considered as potential source of neutropenia. Thus, the eight cycles 
delivered in the experimental group were de facto more prone to cause neutropenic events 
compared to the six cycles in the standard group. The former received also G-CSF and 
antibiotics per protocol requirements, making potential comparison meaningless and 
methodologically unsound.  
The safety of G-CSF administration has been questioned after recognition of expression of 
myeloid growth factor receptors in hematopoietic cells (341). G-CSF support has been 
reported to slightly increase the risk for secondary malignancies such AML/MDS (RR=1.85, 
95% CI 1.19 – 2.88), while simultaneously improving overall survival (RR=0.92, 95% CI 
0.90 – 0.95) (342). The risk of overtreatment with G-CSF needs to be considered and 
adherence to international guidelines is crucial. In the investigated chemotherapy schedules in 
paper III, supportive treatment with G-CSF was beneficial and outweighed potential long-
term side effects, not least considering the low incidence of AML/MDS reported in the study 
(92).  
Although may be contra-intuitive, dose dense treatment schedules are reported to cause less 
leukopenia, mainly due to the practically mandatory and selective administration of G-CSF 
during these schedules compared to the standard regimens (89). G-CSF support resulted in 
fewer dose reductions and delays due to neutropenia even in the standard group. This 
becomes more obvious after comparing compliance to planned treatment among participants 
treated with standard chemotherapy, before and after the policy change. Increased use of G-
CSF improved adherence to the study treatment, in regards to delays and dose reductions due 
to neutropenic events. The latter highlights the benefit of G-CSF even in standard 
chemotherapy regimens in breast cancer, considering the detrimental effect that a reduction in 
relative dose intensity can have on breast cancer outcomes (95, 265). Increased incidence of 
infections with normal ANC when G-CSF was administered, probably reflect infections that 
would still appear, but the G-CSF treated patients were able to hold a normal neutrophil 
count.  
 
Paper IV  
Moving forward, paper IV investigated if tailored dose dense chemotherapy would also 
increase gonadal toxicity and thus affect breast cancer outcomes. Risk for chemotherapy-
induced amenorrhea, at two years after randomisation, among women that did not receive 
GnRHa was equal in both treatment groups. One explanation for this could be the tailoring 
part of trial design. Chemotherapy dose was escalated for patients who did not experience 
severe toxicity but it was also de-escalated for patients that did. Thus, patients that in the 
standard group might had been overtreated, in the experimental group they received a dose 
adapted to their individual. Similarly, patients that required dose escalation would have 
probably been undertreated in the standard group. It would therefore be rational to assume 
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that iatrogenic premature ovarian suppression was equal in the two groups due to the dose 
adjustments depending on toxicity in the experimental group.  
At the same time, other confounding factors could have influenced the results. Patients that 
received GnRHa were excluded from the amenorrhea analysis since amenorrhea due to 
chemotherapy was the endpoint of the analysis. However, GnRHa was based on the treating 
physician’s recommendation and not on random allocation, and may thus mask CIA 
incidence. Moreover, GnRHa administration during chemotherapy seems to have a protective 
effect on ovarian function and can potentially alter the results but such information is lacking 
and this practice was not widely applied during the conduct of the PANTHER trial (310).  
Chemotherapy-induced amenorrhea is associated with improved breast cancer outcomes 
(296, 313, 314). It has been speculated by many that the driver of dose dense chemotherapy 
effect is no other than higher CIA incidence due to increased cumulative doses. This is 
however contradicted by the similar amenorrhea rate between the two treatment groups in the 
PANTHER trial and by analogous results from other trials comparing dose dense and 
standard chemotherapy regimens (305, 316). Thus, treatment efficacy of dose dense 
chemotherapy appears to be related to genuine cytotoxic effect rather than consequence of 
higher rate of premature ovarian insufficiency. Comparison of BCRFS between 
premenopausal women that suffer cessation of menstruation and those who did not was not 
feasible due to the limited number of premenopausal women that experienced breast cancer 
relapse events.  
In the overall population, regardless breast cancer histological subtype, tailored dose dense 
chemotherapy led to a non-significant improvement in BCRFS in both premenopausal and 
postmenopausal women. However, no formal interaction was demonstrated, implying that the 
beneficial effect of experimental treatment, even if not statistically significant, was due to 
increased dose intensity and density, regardless menstruation status at time of chemotherapy 
delivery. 
Subgroup analysis by tumour subtype revealed a positive interaction between menopausal 
status and allocated treatment for women with triple negative breast cancer. There was a non-
statistically significant trend to worse BCRFS among premenopausal women treated with 
tailored dose dense chemotherapy. On the contrary, improved BCRFS was observed among 
postmenopausal women in the same treatment group. The aforementioned menopause status-
allocated treatment interaction did not persist when only hormone receptor negative patients 
were included, probably due to the improved outcomes of the HER2 positive patients due to 
trastuzumab masking other effects. If this finding is an aftereffect of the patients’ younger age 
in the premenopausal group rather than menstruation status itself, then similar findings should 
be present in the overall analysis and the other subgroups analysis. Additionally, based on the 
report of the main results of the PANTHER trial and the EBCTCG meta-analysis, dose dense 
chemotherapy effect is independent of age and ER status (89, 92). Thus, same effect of the 
tailored dose dense chemotherapy would be expected in both hormone-receptor positive and 
negative women, facts suggesting our findings are most probably a chance finding.  
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While acknowledging the risk for false positive findings, potentially yet unknown biological 
factors leading to worse prognosis in young, premenopausal women with tumours lacking 
receptors for treatment other than chemotherapy, should not be disregarded. Randomisation 
in clinical trials is expected to balance known and unknown baseline factors but an 
exploratory sub-group analysis is more prone to biases. Thus, while considering pitfalls in the 
study design, these results should raise caution and be further investigated.  
 
FUTURE PERSPECTIVES 
In addition to the valuable information retrieved from the studies, some reflections warrant 
further investigation and could consist future research activities: 
1. What oncological treatment did the patients in paper I receive and did results of 
similar heart failure outcomes persist after adjusting for chemotherapy and left-sided 
radiotherapy? 
2. The reasons leading to significantly lower administration of device therapy as 
measure to treat heart failure among women with breast cancer history merits further 
investigation. Considering the usual chronic nature of heart failure, can longer follow-
up reveal significant differences in heart failure outcomes?  
3. We, partly, move towards more anthracycline-free regimens with anthracycline-free 
neoadjuvant therapy and salvage with T-DM1 and there is also an increasing trend in 
adjuvant paclitaxel in combination with trastuzumab for early HER2 positive breast 
cancer. Would an anthracycline-free regimen lead to fewer discontinuations of 
trastuzumab due to cardiotoxicity? Would the long-term cardiotoxicity risk after 
trastuzumab be positively affected and can then the overall benefit of trastuzumab 
subsequently increase without the trade-off of anthracycline cardiotoxicity?  
4. As described, there are compelling data on the usefulness of increased chemotherapy 
intensity in high-risk breast cancer. Tailored dose-dense chemotherapy in the 
PANTHER trial significantly improved event-free survival and although 
improvement in overall survival did not reach significance it clearly indicates a trend 
to better survival. Would there be a place for a randomised controlled trial between 
dose dense and tailored dose dense chemotherapy?  
5. G-CSF is indicated when expected neutropenic fever rates exceed 20%. Could G-CSF 
also be useful in the treatment of frail patients with lower estimated neutropenic fever 
risk? Would it allow for more patients to receive chemotherapy; both (neo)adjuvant 
and in metastatic disease? Would it be clinically relevant and/or cost-effective? 
6. Further follow-up is justified to investigate long-term survival effect of CIA among 
the premenopausal PANTHER patients due to the long natural history of ER-positive 
disease. 
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7. Can we gather individual patient data from other dose-dense chemotherapy studies to 
investigate interaction of dose dense chemotherapy and menopausal status in a larger 
triple negative breast cancer population? 
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CONCLUSION 
Breast cancer is the most common cancer among women in most countries. The constantly 
improving prognosis of breast cancer, almost 8 out of 10 women diagnosed with breast 
cancer are alive after 10 years, has led to increasing number of long-term survivors. 
Management of early breast cancer is multiprofessional involving various disciplines and 
treatment approaches. In addition, the median age of diagnosis (around 60-65 years in 
Europe) coincides with an age when also the risk for cardiovascular disease and other 
comorbidities increases. Thus, breast cancer therapy is further perplexed with an important 
ethical dilemma; provide enough care to survive a potentially life-threatening disease as 
cancer and concurrently keep unwanted short and long-term effects of surgery, 
chemotherapy, targeted therapy and radiotherapy at the minimum. Or as Hippocrates said, to: 
“follow that system of regimen which, according to my ability and judgment, I consider for 
the benefit of my patients, and abstain from whatever is deleterious and mischievous”. The 
“primum non nocere”. As such, our studies aimed to better characterise heart failure after 
breast cancer diagnosis and to investigate trastuzumab-related cardiotoxicity, neutropenic 
events and premature ovarian insufficiency related to intensified breast cancer chemotherapy 
regimens. 
In conclusion: 
- History of breast cancer did not predict a worse heart failure prognosis, despite 
observed differences in the management of heart failure. The differences 
demonstrated in the frequency of ischemic heart disease and administration of aspirin 
and, more importantly, device therapy highlight the need for development of heart 
failure management guidelines adapted to the need of the cancer patient and cancer 
survivors. Longer follow-up is warranted and will shed more light in the impact of 
differences in heart failure management among women with prevalent heart failure 
with and without breast cancer. Collaboration between cardiologists and oncologists 
is essential for the assessment and management of patients at risk for cardiotoxicity 
and those who develop cardiac adverse events related to cancer therapy.        
- The combination of dose-dense chemotherapy and trastuzumab decreased the relative 
risk for relapse by 32%, compared to standard treatment, a statistically non-significant 
difference. The combination was feasible and did not lead to increased cardiotoxicity, 
until six years of follow-up. Longer follow-up is warranted to assess long-term 
cardiotoxicity and efficacy.  
- Prophylactic G-CSG allowed for dose escalation without excess neutropenia related 
adverse events and, significantly, no neutropenia-related deaths were observed in the 
study. In line with existing data, G-CSF support reduced neutropenic events and dose 
reductions, allowing for increased relative dose intensity, an important factor for 
improved survival outcomes. These results come to add in the significance of 
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appropriate use of G-CSF prophylaxis in both standard and dose dense breast cancer 
chemotherapy regimens. 
- Tailored and dose-dense adjuvant chemotherapy did, thus far, not increase risk for 
CIA and was associated with statistically non-significant improvements in outcomes 
compared with standard therapy, regardless of menopausal status and amenorrhea. It 
is uncertain whether there is a plausible biological explanation for the observed 
negative effect of tailored and dose-dense chemotherapy among premenopausal 
patients with triple negative breast cancer or it is merely due to a chance finding. 
Nonetheless, these results further support the efficacy of dense chemotherapy 
independent of CIA.  
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